Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID
Authors
Title External Reference Not Available (N/A)
Journal Vol Issue Date Pages Journal Short Title
URL https://ckb.jax.org/about/glossaryOfTerms
Abstract Text This reference is often associated with concepts defined in CKB when other references are not available. For example, category variants, non-specific variants, or drugs with limited information.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
123I-ATT001 123I-ATT001 0 1
177Lu-AKIR001 177Lu-AKIR001 0 1
177Lu-R11228 177Lu-R11228 0 1
177Lu-RAD202 177Lu-RAD202 0 1
225Ac-A9-3408 225Ac-A9-3408 0 1
ABBV-151 + Budigalimab ABBV-151 Budigalimab 0 4
ABBV-324 ABBV-324 0 1
ABBV-368 + ABBV-927 + Budigalimab ABBV-368 ABBV-927 Budigalimab 0 1
ABBV-969 ABBV-969 0 1
ABP 206 ABP 206 0 1
ABP 234 ABP 234 0 0
ABX-001 ABX-001 0 1
Ac-225-PSMA-62 Ac-225-PSMA-62 0 1
Activated PTCgamma MILs Activated PTCgamma MILs 0 1
Adze1.C Adze1.C 0 1
AG-270 AG-270 0 1
AK138D1 AK138D1 0 1
AK146D1 AK146D1 0 1
ALE.P02 ALE.P02 0 1
ALE.P03 ALE.P03 0 0
ALK202 ALK202 0 1
ALKS 4230 + Pembrolizumab ALKS 4230 Pembrolizumab 0 4
ALX2004 ALX2004 0 1
AMG 596 AMG 596 0 1
AMO959 AMO959 0 0
AMT-676 AMT-676 0 1
AMT-754 AMT-754 0 1
AMX-500 AMX-500 0 1
ANV419 ANV419 0 3
AP601 AP601 0 1
ARQ 751 ARQ 751 11 1
ART4215 ART4215 0 1
ARV-806 ARV-806 0 1
ASP101G ASP101G 0 0
ASP1948 ASP1948 0 1
ASP5834 ASP5834 0 1
AST-008 + Pembrolizumab AST-008 Pembrolizumab 0 1
Atezolizumab + Uliledlimab Atezolizumab Uliledlimab 0 1
ATP152 ATP152 0 0
ATP162 ATP162 0 0
AUBE00 AUBE00 0 1
Autogene cevumeran + Pembrolizumab Autogene cevumeran Pembrolizumab 0 1
Autologous KRAS mutant TCR-transduced PBLs Autologous KRAS mutant TCR-transduced PBLs 0 0
AVZO-103 AVZO-103 0 1
AVZO-1418 AVZO-1418 0 1
AXN-2510 AXN-2510 0 1
AZD2275 AZD2275 0 0
AZD2287 AZD2287 0 0
AZD2962 AZD2962 0 1
AZD3632 AZD3632 0 1
AZD4360 AZD4360 0 1
AZD4512 AZD4512 0 2
AZD6750 AZD6750 0 1
BAY 3547926 BAY 3547926 0 1
BAY 3713372 BAY 3713372 0 1
BEAM-201 BEAM-201 0 2
BG-75098 BG-75098 0 1
BG-75202 BG-75202 0 1
BG-89894 BG-89894 0 0
BGB-B455 BGB-B455 0 1
BI 3810944 BI 3810944 0 1
BI 765883 BI 765883 0 1
BL-M14D1 BL-M14D1 0 1
BL-M17D1 BL-M17D1 0 1
BL0020 BL0020 0 1
BM230 BM230 0 1
BMS-986183 BMS-986183 0 1
BMS-986226 BMS-986226 0 1
BMS-986277 BMS-986277 0 1
BMS-986298 BMS-986298 0 3
BMS-986463 BMS-986463 0 1
BMS-986482 BMS-986482 0 1
BMS-986484 BMS-986484 0 1
BMS-986488 BMS-986488 0 1
BMS-986489 BMS-986489 0 1
BMS-986490 BMS-986490 0 1
BMS-986500 BMS-986500 0 1
BMS-986506 BMS-986506 0 1
BMS-986517 BMS-986517 0 1
BMS-986523 BMS-986523 0 1
BNA035 BNA035 0 1
BNT142 BNT142 0 1
BNT317 BNT317 0 1
BNT3212 BNT3212 0 1
BP1001-A BP1001-A 0 1
C-TIL051 C-TIL051 0 0
C7R.CD30.CAR-EBVS T-cells C7R.CD30.CAR-EBVS T-cells 0 1
CAL056 mesylate CAL056 mesylate 0 1
CAR.5/IL15-transduced CB-NK cells CAR.5/IL15-transduced CB-NK cells 0 1
CAR19-tTreg CAR19-tTreg 0 1
CBP-1019 CBP-1019 0 1
CD19CAR(2G)-T2A-HER2tG + EGFR806CAR(2G)-EGFRt CD19CAR(2G)-T2A-HER2tG EGFR806CAR(2G)-EGFRt 0 1
CD371-YSNVZIL-18 CAR T cells CD371-YSNVZIL-18 CAR T cells 0 1
CD7-CART01 cells CD7-CART01 cells 0 1
CD70.CAR NK cells CD70.CAR NK cells 0 0
Cetuximab + TPST-1120 Cetuximab TPST-1120 0 1
CHS-006 CHS-006 0 0
CP-383 CP-383 0 1
CPI-200 CPI-200 0 1
CV09070101 CV09070101 0 1
Cyclophosphamide + EG12014 + Epirubicin + Paclitaxel Cyclophosphamide EG12014 Epirubicin Paclitaxel 0 1
Cyclophosphamide + NeoVax Cyclophosphamide NeoVax 0 1
CYT-101 CYT-101 0 0
DB-1202 DB-1202 0 1
DB-1317 DB-1317 0 1
DCC-2812 DCC-2812 0 1
DCR-PDL1 DCR-PDL1 0 1
DCR-STAT3 DCR-STAT3 0 1
Debio 4228 Debio 4228 0 1
Descartes-15 Descartes-15 0 1
Descartes-25 Descartes-25 0 1
DF9001 DF9001 0 1
DR-0202 DR-0202 0 1
DS5361b DS5361b 0 1
DS9051b DS9051b 0 1
DZ-002 DZ-002 0 1
ECI830 ECI830 0 1
ENV-501 ENV-501 0 1
EOS006215 EOS006215 0 1
ERAS-9 ERAS-9 0 0
ETBX-021 ETBX-021 0 2
EVM14 EVM14 0 1
Exemestane + GS-5829 Exemestane GS-5829 0 3
FHA-11 KRAS G12V-TCR FHA-11 KRAS G12V-TCR 0 1
FK-PC101 FK-PC101 0 1
Fluorouracil + Irinotecan + Leucovorin + TRK-950 Fluorouracil Irinotecan Leucovorin TRK-950 0 1
GCAR1 GCAR1 0 1
GEN1056 GEN1056 0 1
GEN1057 GEN1057 0 1
GEN1078 GEN1078 0 1
GH52 GH52 0 0
GRN-1201 GRN-1201 0 0
GS-2121 GS-2121 0 1
GS-4528 GS-4528 0 1
GS-5319 GS-5319 0 1
GSK3745417 + Pembrolizumab GSK3745417 Pembrolizumab 0 1
GSK5458514 GSK5458514 0 1
HCB301 HCB301 0 1
HER2-pulsed DC1 vaccine HER2-pulsed DC1 vaccine 0 8
HLD-0915 HLD-0915 0 1
HLX-1502 HLX-1502 0 1
HMPL-453 HMPL-453 1 0
HRS-3802 HRS-3802 0 1
HRS-5041 HRS-5041 0 1
HS-110 HS-110 0 1
HS-20110 HS-20110 0 1
HTR2 T cells HTR2 T cells 0 1
HX-044 HX-044 0 1
IACS-6274 + Paclitaxel IACS-6274 Paclitaxel 0 1
IBI129 IBI129 0 1
IBI130 IBI130 0 1
IBI3009 IBI3009 0 1
IBI3020 IBI3020 0 1
IDE849 IDE849 0 1
IDOV-Immune IDOV-Immune 0 1
II-11 II-11 0 0
IMA202 IMA202 0 1
IMC-P115C IMC-P115C 0 1
IMC-R117C IMC-R117C 0 1
IMU-935 IMU-935 0 1
INBRX-106 INBRX-106 0 1
INCB186748 INCB186748 0 1
IPN01195 IPN01195 0 1
iTCR-transduced PBL iTCR-transduced PBL 0 0
IVAC IVAC 0 1
IVT-8086 IVT-8086 0 0
JAB-23E73 JAB-23E73 0 1
JNJ-70218902 JNJ-70218902 0 1
JNJ-87562761 JNJ-87562761 0 1
JNJ-88998377 JNJ-88998377 0 1
JNJ-89402638 JNJ-89402638 0 1
JNJ-89862175 JNJ-89862175 0 1
JNJ-90009530 JNJ-90009530 0 1
JNJ-90189892 JNJ-90189892 0 1
JNJ-90301900 JNJ-90301900 0 0
JNJ-95437446 JNJ-95437446 0 1
JSKN033 JSKN033 0 1
KBA1412 KBA1412 0 1
KFA115 KFA115 0 1
KITE-718 KITE-718 0 2
KQB168 KQB168 0 1
KQB548 KQB548 0 1
KTX-2001 KTX-2001 0 1
KUR-502 KUR-502 0 1
LB-LR1109 LB-LR1109 0 1
LM-061 LM-061 0 1
LM-299 LM-299 0 1
LSZ 102 LSZ 102 0 1
LTG2950 LTG2950 0 1
LTZ-301 LTZ-301 0 1
LVGN6501 LVGN6501 0 0
LY4257496 LY4257496 0 0
LY4337713 LY4337713 0 1
LY4584180 LY4584180 0 1
LZM009 LZM009 0 1
M3T01 M3T01 0 1
MAQ-001 MAQ-001 0 1
MB-dNPM1-TCR.1 MB-dNPM1-TCR.1 0 1
MBF-362 MBF-362 0 1
MBRC-201 MBRC-201 0 1
MDX2004 MDX2004 0 1
MEDI5083 MEDI5083 0 1
MEDI7247 MEDI7247 0 2
MEDI9090 MEDI9090 0 0
MEN2501 MEN2501 0 1
MK-1088 MK-1088 0 1
MK-1308 MK-1308 0 1
MK-1484 MK-1484 0 1
MK-3120 MK-3120 0 1
MK-4700 MK-4700 0 1
MK-6837 MK-6837 0 1
MK-8294 MK-8294 0 1
MNPR-101-PCTA-177Lu MNPR-101-PCTA-177Lu 0 2
MPT-0118 MPT-0118 0 1
mRNA plus lysate-loaded dendritic cell vaccine mRNA plus lysate-loaded dendritic cell vaccine 0 0
mRNA-2736 mRNA-2736 0 1
mRNA-2808 mRNA-2808 0 1
mRNA-4106 mRNA-4106 0 1
mRNA-4203 mRNA-4203 0 0
MS201408-0005A MS201408-0005A 0 1
MS201408-0005B MS201408-0005B 0 0
MS201408-0005C MS201408-0005C 0 0
MSB2311 MSB2311 0 1
MT-601 MT-601 0 1
NDI-219216 NDI-219216 0 1
NEO-PV-01 NEO-PV-01 0 0
Neoantigen-targeted ppDC Neoantigen-targeted ppDC 0 1
NeoVax NeoVax 0 2
NG101m NG101m 0 0
Nivolumab + Olutasidenib Nivolumab Olutasidenib 0 1
Nivolumab + RP1 Nivolumab RP1 0 2
Nivolumab + SER-401 Nivolumab SER-401 0 1
NKT5097 NKT5097 0 1
NRM-823 NRM-823 0 1
NT-175 NT-175 0 1
NTS071 NTS071 0 1
NUV-868 NUV-868 0 1
NY-ESO-1 TCR CD4- CD34+ HSC NY-ESO-1 TCR CD4- CD34+ HSC 0 1
ODM-212 ODM-212 0 1
OKN4395 OKN4395 0 1
ORB-021 ORB-021 0 1
OSE-279 OSE-279 0 1
OT-A201 OT-A201 0 1
OTS167PO OTS167PO 0 0
P30-EPS P30-EPS 0 0
PalloV-CC PalloV-CC 0 1
Pembrolizumab + XmAb22841 Pembrolizumab XmAb22841 0 1
PEP08 PEP08 0 1
Peptide vaccine IPX Peptide vaccine IPX 0 1
PF-06688992 PF-06688992 0 1
PF-06755990 PF-06755990 0 0
PF-06940434 PF-06940434 0 1
PF-07225570 PF-07225570 0 1
PF-07329640 PF-07329640 0 1
PF-08052667 PF-08052667 0 1
PHN-012 PHN-012 0 1
PT0253 PT0253 0 1
QEQ278 QEQ278 0 1
RC198 RC198 0 1
REGN4336 REGN4336 0 1
RM-007 RM-007 0 0
RM-008 RM-008 0 0
RM-1995 RM-1995 0 1
RNK08954 RNK08954 0 1
RO7296682 RO7296682 0 1
RO7566802 RO7566802 0 1
RO7567132 RO7567132 0 0
RO7673396 RO7673396 0 1
RO7759065 RO7759065 0 1
RPCAR01 RPCAR01 0 1
RR001 RR001 0 0
S095029 S095029 0 1
SBO-154 SBO-154 0 1
SDGR5 SDGR5 0 0
SG2501 SG2501 0 1
SIM0505 SIM0505 0 1
SL-901 SL-901 0 1
SLV-154 SLV-154 0 1
SLV-324 SLV-324 0 1
SPL-108 SPL-108 0 1
SPYK04 SPYK04 0 1
SQZ-AAC-HPV SQZ-AAC-HPV 0 1
SSGJ-709 SSGJ-709 0 1
ST-01156 ST-01156 0 1
STIL101 STIL101 0 0
SV-102 SV-102 0 1
SY-2101 SY-2101 0 1
Sym022 Sym022 0 1
SynKIR-310 SynKIR-310 0 1
TAK-188 TAK-188 0 1
Tarcidomgen kimleucel Tarcidomgen kimleucel 0 1
TBI-2001 TBI-2001 0 1
TBio-6517 TBio-6517 0 1
TCRT-ESO-A2 TCRT-ESO-A2 0 1
TEIPP24 TEIPP24 0 1
TER-2013 TER-2013 0 1
TGN-S11 TGN-S11 0 1
TLN-121 TLN-121 0 1
TLN-254 TLN-254 0 1
TLN-372 TLN-372 0 1
TP-1454 TP-1454 0 1
TRPH 011 TRPH 011 0 0
TSC-201-B0702 TSC-201-B0702 0 1
TSC-204-A0101 TSC-204-A0101 0 1
VERT-002 VERT-002 0 1
VIR-5525 VIR-5525 0 1
VLPONC-01 VLPONC-01 0 1
VVD-159642 VVD-159642 0 1
WEF-001 WEF-001 0 1
X4P-001 X4P-001 0 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
123I-ATT001 123I ATT001|123IATT001 PARP Inhibitor (Pan) 29 Limited information is currently available on 123I-ATT001, a putative PARP inhibitor linked to the radioisotope I 123 (Oct 2024).
177Lu-AKIR001 [177Lu]Lu-AKIR001 Limited information is currently available on 177Lu-AKIR001, a putative radiotherapy targeting CD44v6 (Oct 2024).
177Lu-R11228 177Lu R11228 Limited information is currently available on 177Lu-R11228 (Oct 2025).
177Lu-RAD202 177LuRAD202|177Lu RAD202|RAD202|RAD 202|RAD-202 HER2 (ERBB2) Antibody 79 Limited information is currently available on 177Lu-RAD202, a putative radiolabeled antibody therapy targeting ERBB2 (HER2) (Mar 2025).
225Ac-A9-3408 [225Ac]Ac-A9-3408|[225Ac]A9-3408 Limited information is currently available on 225Ac-A9-3408 (Jul 2025).
ABBV-324 ABBV324|ABBV 324 Limited information is currently available on ABBV-324 (May 2025).
ABBV-969 ABBV 969|ABBV969 PSMA Antibody 22 ABBV-969 is an antibody-drug conjugate (ADC) comprising an antibody targeting PSMA and STEAP1 linked to a topoisomerase I inhibitor payload, which potentially induces tumor cell death (Ann Oncol 35 (2024): S1000-S1001, NCI Drug Dictionary).
ABP 206 ABP206|ABP-206 Limited information is currently available on ABP 206, a putative Opdivo (nivolumab) biosimilar (Oct 2023).
ABP 234 ABP234|ABP-234 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 Limited information is currently available on ABP 234, a putative Keytruda (pembrolizumab) biosimilar (Sep 2024).
ABX-001 ABX 001|ABX001 Limited information is currently available on ABX-001, a putative optimized arenavirus vector with tumor-tropic mutations (Nov 2025).
AK138D1 AK 138D1|AK-138D1|AK138 D1|AK138-D1 Limited information is currently available on AK138D1 (Dec 2024).
AK146D1 AK146-D1|AK-146D1|AK 146D1 TROP2 Antibody 18 Limited information is currently available on AK146D1, a putative bispecific antibody-drug conjugate (ADC) targeting Trop2 and Nectin4 (Jul 2025).
ALE.P02 ALEP02|ALE P02|ALE PO2|ALE.PO2 Limited information is currently available on ALE.P02, a putative antibody-drug conjugate targeting CLDN1 (Feb 2025).
ALE.P03 ALEP03|ALE P03 Limited information is currently available on ALE.P03, a putative antibody-drug conjugate targeting CLDN1 (Feb 2025).
ALK202 ALK 202|ALK-202 EGFR Antibody 72 MET Antibody 37 Limited information is currently available on ALK202, a putative bispecific antibody-drug conjugate (ADC) targeting EGFR and MET (Mar 2025).
ALX2004 ALX 2004|ALX-2004 EGFR Antibody 72 Limited information is currently available on ALX2004, a putative antibody-drug conjugate (ADC) targeting EGFR (Jul 2025).
AMO959 AMO 959|AMO-959|BY1298|BY101298 Limited information is currently available on AMO959, a putative DNA damage response inhibitor (Dec 2025).
AMT-676 AMT676|AMT 676 Limited information is currently available on AMT-676 (May 2024).
AMT-754 AMT754|AMT 754 Limited information is currently available on AMT-754, a putative antibody-drug conjugate (ADC) targeting tissue factor (TF) (Oct 2024).
AMX-500 AMX500|AMX 500|SAR446329|SAR-446329|SAR 446329|VIR-5500|VIR5500 Limited information is currently available on AMX-500 (SAR446329) (Sep 2023).
ANV419 ANV 419|ANV-419 ANV419 is a fusion protein comprised of the cytokine IL-2 and an antibody that blocks the CD25 binding site of IL-2, which retains binding to CD122 and may lead to increased proliferation of CD8 T cells and NK cells and inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021;9).
AP601 AP-601|AP 601 CD73 Antibody 14 TNFRSF9 Antibody 36 Limited information is currently available on AP601, a putative bispecific antibody targeting NTSE (CD73) and TNFRSF9 (CD137, 4-1BB) (Sep 2025).
ART4215 ART-4215|ART 4215 ART4215 inhibits DNA polymerase theta and prevents DNA damage repair, potentially leading to enhanced sensitivity to DNA damaging agents (NCI Drug Dictionary).
ARV-806 ARV806|ARV 806 KRAS G12D Inhibitor 25 Limited information is currently available on ARV-806, a putative KRAS G12D degrader (Jun 2025).
ASP101G ASP 101G|ASP-101G|MA-20|MA20 Limited information is currently available on ASP101G (Jul 2024).
ASP5834 ASP-5834|ASP 5834 KRAS Inhibitor 30 Limited information is currently available on ASP5834, a putative pan-KRAS degrader (Aug 2025).
ATP152 ATP-152|ATP 152 Limited information is currently available on ATP152, a putative therapeutic protein vaccine (May 2023).
ATP162 ATP-162|ATP 162 Limited information is currently available on ATP162 (Oct 2025).
AUBE00 AUBE-00|AUBE 00 KRAS Inhibitor 30 Limited information is currently available on AUBE00, a putative cyclic peptide that inhibits KRAS (Aug 2025).
AVZO-103 AVZO103|AVZO 103 TROP2 Antibody 18 Limited information is currently available on AVZO-103, a putative bispecific antibody targeting Nectin4 and Trop2 (Sep 2025).
AVZO-1418 AVZO1418|AVZO1418 EGFR Antibody 72 HER3 (ERBB3) Antibody 28 Limited information is currently available on AVZO-1418, a putative bispecific antibody-drug conjugate (ADC) targeting EGFR and ERBB3 (HER3) (Jul 2025).
AXN-2510 AXN 2510|AXN2510 PD-L1/PD-1 antibody 132 VEGF Antibody 15 Limited information is currently available on AXN-2510, a putative bispecific antibody targeting CD274 (PD-L1) and VEGF (Sep 2025).
AZD2275 AZD-2275|AZD 2275 Limited information is currently available on AZD2275 (Mar 2025).
AZD2287 AZD-2287|AZD 2287 Limited information is currently available on AZD2287 (Mar 2025).
AZD2962 AZD-2962|AZD 2962 IRAK4 Inhibitor 8 Limited information is currently available on AZD2962, a putative IRAK4 inhibitor (Jul 2025).
AZD3632 AZD-3632|AZD 3632 Limited information is currently available on AZD3632 (Sep 2025).
AZD4360 AZD-4360|AZD 4360 CLDN18.2 Antibody 23 Limited information is currently available on AZD4360, a putative antibody-drug conjugate (ADC) targeting CLDN18.2 (Apr 2025).
AZD4512 AZD-4512|AZD 4512 Limited information is currently available on AZD4512 (Aug 2025).
AZD6750 AZD 6750|AZD-6750 Limited information is currently available on AZD6750, a CD8-guided IL-2 therapeutic (Aug 2025).
Ac-225-PSMA-62 Ac225-PSMA-62|225Ac-PSMA-62 Limited information is currently available on Ac-225-PSMA-62, a putative radioligand therapy targeting PSMA (Jun 2024).
Activated PTCgamma MILs Limited information is currently available on activated PTCgamma MILs (Apr 2023).
Adze1.C Limited information is currently available on Adze1.C, a putative oncolytic virus therapy (Jul 2025).
Autologous KRAS mutant TCR-transduced PBLs Autologous KRAS mutant TCR-transduced PBLs are peripheral blood lymphocytes engineered to express a T-cell receptor (TCR) specific for a KRAS mutation, which potentially induce cytotoxic T-lymphocyte (CTL)-dependent killing of tumor cells expressing mutant KRAS (NCI Drug Dictionary).
BAY 3547926 BAY3547926|BAY-3547926 Limited information is currently available on BAY 3547926, a putative radiotherapy (Jan 2025).
BAY 3713372 BAY-3713372|BAY3713372 PRMT5 Inhibitor 21 Limited information is currently available on BAY 3713372, a putative PRMT5 inhibitor (Apr 2025).
BEAM-201 BEAM 201|BEAM201 CD7 Immune Cell Therapy 4 BEAM-201 comprises allogeneic T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD7 and to harbor mutations in TRAC, CD7, CD52, and PDCD1, which potentially induces killing of tumor cells expressing CD7 (Blood (2024) 144 (Supplement 1): 4838, NCI Drug Dictionary).
BG-75098 BG75098|BG 75098 Limited information is currently available on BG-75098, a putative Cdk2 degrader (Nov 2025).
BG-75202 BG 75202|BG75202 Limited information is currently available on BG-75202, a putative KMT2A/B inhibitor (Nov 2025).
BG-89894 BG89894|BG 89894|SYH2039|SYH 2039|SYH-2039 Limited information is currently available on BG-89894, a putative MAT2A inhibitor (Sep 2025).
BGB-B455 BGBB455|BGB B455 CD3 Antibody 119 CLDN6 Antibody 10 Limited information is currently available on BGB-B455, a putative bispecific antibody targeting CLDN6 on tumor cells and CD3 on T-cells (Mar 2025).
BI 3810944 BI-3810944|BI3810944 Limited information is currently available on BI 3810944 (Nov 2025).
BI 765883 BI-765883|BI765883 Limited information is currently available on BI 765883 (Oct 2024).
BL-M14D1 BL M14D1|BLM14D1 Limited information is currently available on BL-M14D1 (Oct 2025).
BL-M17D1 BL M17D1|BLM17D1 HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 Limited information is currently available on BL-M17D1, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) (Jun 2025).
BL0020 BL-0020|BL 0020 Limited information is currently available on BL0020 (Oct 2023).
BM230 BM-230|BM 230 Limited information is currently available on BM230, a putative natural killer cell engager (Dec 2024).
BMS-986183 BMS986183|BMS 986183 GPC3 Antibody 7 Limited information is currently available on BMS-986183, a putative antibody drug conjugate targeting Glypican-3 (GPC3) (Apr 2023).
BMS-986277 BMS 986277|BMS986277 Limited information is currently available on BMS-986277, a putative oncolytic adenovirus expressing CD80 that is selective for epithelial cells (Apr 2023).
BMS-986298 BMS 986298|BMS986298 Immune Checkpoint Inhibitor 150 Limited information is available on BMS-986298, a putative subcutaneous formulation of nivolumab (Apr 2023).
BMS-986463 BMS 986463 Limited information is currently available on BMS-986463 (Jul 2024).
BMS-986482 BMS986482|BMS 986482 Limited information is currently available on BMS-986482 (Nov 2024).
BMS-986484 BMS986484|BMS 986484 Limited information is currently available on BMS-986484 (Aug 2024).
BMS-986488 BMS986488|BMS 986488 Limited information is currently available on BMS-986488 (Jan 2025).
BMS-986489 BMS986489|BMS 986489 Limited information is available on BMS-986489, a putative formulation of BMS-986012 and nivolumab (Feb 2025).
BMS-986490 BMS 986490|BMS986490 Limited information is currently available on BMS-986490 (Dec 2024).
BMS-986500 BMS 986500|BMS986500 Limited information is currently available on BMS-986500 (Jun 2025).
BMS-986506 BMS986506|BMS 986506 Limited information is currently available on BMS-986506 (Oct 2025).
BMS-986517 BMS 986517|BMS986517 Limited information is currently available on BMS-986517 (Sep 2025).
BMS-986523 BMS 986523|BMS986523 Limited information is currently available on BMS-986523 (Nov 2025).
BNA035 BNA-035|BNA 035|HLX35|HLX 35|HLX-35 EGFR Antibody 72 TNFRSF9 Antibody 36 BNA035 is a bi-specific antibody that binds EGFR and 4-1BB, potentially resulting in increased anti-tumor immune response and lysis of tumor cells expressing EGFR (NCI Drug Dictionary).
BNT142 BNT-142|BNT 142 BNT142 consists of an mRNA encoding a bispecific anti-Claudin 6 (CLDN6) and anti-CD3 antibody encapsulated in a lipid nanoparticle, which potentially leads to activation and proliferation of T-lymphocytes and cytotoxic T-lymphocyte mediated cell death of CLDN6-expressing tumor cells (NCI Drug Dictionary).
BNT317 Limited information is currently available on BNT317 (Feb 2025).
BNT3212 BNT-3212|BNT 3212 EGFR Antibody 72 HER3 (ERBB3) Antibody 28 Limited information is currently available on BNT3212, a putative EGFR/ERBB3 (HER3)-targeted antibody-drug conjugate (ADC) (Oct 2025).
BP1001-A BP-1001-A|BP 1001-A Limited information is currently available on BP1001-A, a putative liposomal anti-Grb2 antisense oligonucleotide (Jun 2024).
C-TIL051 CTIL051|C TIL051 C-TIL051 are tumor-derived autologous tumor infiltrating lymphocytes (TILs), which induce killing of tumor cells (NCI Drug Dictionary).
C7R.CD30.CAR-EBVS T-cells C7R.CD30.CAR-EBVST cells CD30 (TNFRSF8) Immune Cell Therapy 5 Limited information is currently available on C7R.CD30.CAR-EBVS T-cells, putative allogeneic T-cells that have been engineered to express constitutive IL7R (C7R) and a chimeric antigen receptor (CAR) targeting TNFRSF8 (CD30) (Feb 2024). 
CAL056 mesylate CAL056 Limited information is currently available on CAL056 mesylate (Apr 2023).
CAR.5/IL15-transduced CB-NK cells Limited information is currently available on CAR.5/IL15-transduced CB-NK cells (Mar 2024).
CAR19-tTreg CD19 Immune Cell Therapy 72 Limited information is currently available on CAR19-tTreg, a putative cell therapy comprising regulatory T-cells expressing an anti-CD19 chimeric antigen receptor (CAR) (Apr 2024).
CBP-1019 CBP 1019|CBP1019 FOLR1-targeted Therapy 24 CBP-1019 is a bispecific ligand-drug conjugate that targets FOLR1 (FRalpha) and TRPV6 and contains exatecan (DX-8951), which potentially inhibits tumor growth (Ann Oncol (2024) 35 (Suppl_2): S512-S513).
CD371-YSNVZIL-18 CAR T cells CD371-specific/YSNVz/IL-18 CAR T-cells CD371-YSNVZIL-18 CAR T cells are T-lymphocytes engineered to express IL-18 and a chimeric antigen receptor (CAR) that targets CLEC12A (CD371), which potentially induce increased antitumor immune response and cytotoxicity against CLEC12A (CD371)-expressing tumor cells (NCI Drug Dictionary).
CD7-CART01 cells CD7CART01 cells|CD7 CART01 cells CD7 Immune Cell Therapy 4 Limited information is currently available on CD7-CART01 cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD7 (Jun 2024).
CD70.CAR NK cells CD70 CAR NK cells|CD70.CAR NK-cells CD70 Immune Cell Therapy 11 Limited information is currently available on CD70.CAR NK cells, putative cord blood-derived natural killer (NK) cells expressing a chimeric antigen receptor (CAR) targeting CD70 (Oct 2025).
CHS-006 CHS 006|CHS006 TIGIT Antibody 20 Limited information is currently available on CHS-006, a putative anti-TIGIT antibody (Apr 2023).
CP-383 CP383|CP 383 Limited information is currently available on CP-383 (Sep 2025).
CPI-200 CPI200 Limited information is currently available on CPI-200 (Apr 2023).
CV09070101 CV-09070101|CV 09070101|CVHNLC Limited information is currently available on CV09070101, a putative mRNA vaccine (Jul 2025).
CYT-101 CYT101|CYT 101 Limited information is currently available on CYT-101, a putative allogeneic CMV-specific T-cell therapy (Dec 2023).
DB-1202 DB1202|DB 1202 Limited information is currently available on DB-1202 (Apr 2023).
DB-1317 DB1317|DB 1317 Limited information is currently available on DB-1317 (Sep 2025).
DCC-2812 DCC 2812|DCC2812 Limited information is currently available on DCC-2812, a putative GCN2 activator (Sep 2025).
DCR-PDL1 DCR PDL1 Limited information is currently available on DCR-PDL1 (Jul 2024).
DCR-STAT3 Limited information is currently available on DCR-STAT3 (Oct 2023).
DF9001 DF-9001|DF 9001 DF9001 is a tri-specific natural killer cell engager therapy that binds to tumor-expressed EGFR and NK cells, potentially inducing an anti-tumor immune response against EGFR-expressing tumor cells (NCI Drug Dictionary).
DR-0202 DR0202|DR 0202 Limited information is currently available on DR-0202, a putative bispecific antibody (Jun 2025).
DS5361b DS5 361b|DS5-361b Limited information is currently available on DS5361b (Sep 2025).
DS9051b DS-9051b|DS 9051b Limited information is currently available on DS9051b (Sep 2025).
DZ-002 DZ 002|DZ002 Limited information is currently available on DZ-002 (Apr 2023).
Debio 4228 Debio-4228 Hormone Antineoplastics 2 Limited information is currently available on Debio 4228, a putative extended release formulation of a gonadotropin-releasing hormone antagonist (Jun 2024).
Descartes-15 Descartes 15|Descartes15 TNFRSF17 Immune Cell Therapy 27 Limited information is currently available on Descartes-15, a putative anti-BCMA mRNA chimeric antigen receptor (CAR) T-cell therapy (Mar 2024).
Descartes-25 Descartes 25|Descartes25 Limited information is currently available on Descartes-25, a putative BCMA and IL-12-targeting therapy (Apr 2023).
ECI830 ECI-830|ECI 830 Limited information is currently available on ECI830 (Apr 2025).
ENV-501 ENV 501|ENV501 HER3 (ERBB3) Antibody 28 Limited information is currently available on ENV-501, a putative antibody-drug conjugate (ADC) targeting ERBB3 (HER3) (May 2025).
EOS006215 EOS-006215|EOS 006215|EOS215|EOS 215|EOS-215 Limited information is currently available on EOS006215, a putative monoclonal antibody targeting TREM2 (Mar 2025).
ERAS-9 ERAS 9|ERAS9 SOS1 Inhibitor 17 Limited information is currently available on ERAS-9, a putative SOS1 inhibitor (Apr 2023).
EVM14 EVM-14|EVM 14 Limited information is currently available on EVM14, a putative mRNA vaccine (Aug 2025).
FHA-11 KRAS G12V-TCR FHA-11KRAS G12V-TCR Limited information is currently available on FHA-11 KRAS G12V-TCR, a putative T-cell therapy targeting KRAS G12V (Apr 2024).
FK-PC101 Limited information is currently available on FK-PC101, a putative personalized cancer vaccine (Oct 2024).
GCAR1 GCAR 1|GCAR-1 Limited information is currently available on GCAR1, a putative chimeric antigen receptor (CAR) T-cell therapy targeting GPNMB (Mar 2025).
GEN1056 GEN-1056|GEN 1056 Limited information is currently available on GEN1056 (Apr 2023).
GEN1057 GEN-1057|GEN 1057 Limited information is currently available on GEN1057 (Sep 2024).
GEN1078 GEN-1078|GEN 1078 Limited information is currently available on GEN1078 (Feb 2025).
GH52 GH-52|GH 52 SOS1 Inhibitor 17 Limited information is currently available on GH52, a putative SOS1 inhibitor (Apr 2023).
GS-2121 GS2121|GS 2121 Limited information is currently available on GS-2121 (Aug 2024).
GS-4528 GS 4528|GS4528 Limited information is currently available on GS-4528 (Jun 2023).
GS-5319 GS5319|GS 5319 Limited information is currently available on GS-5319 (Sep 2025).
GSK5458514 GSK 5458514|GSK-5458514 PSMA Antibody 22 Limited information is currently available on GSK5458514, a putative T-cell engager targeting PSMA (Jul 2025).
HCB301 HCB-301|HCB 301 Limited information is currently available on HCB301, a putative anti-CD274 (PD-L1)/SIRPalpha/TGFbeta trap fusion protein (Apr 2025).
HER2-pulsed DC1 vaccine HER2-pulsed type-1 polarized autologous dendritic cell vaccine HER2 (ERBB2) Vaccine 15 HER2-pulsed DC1 vaccine is a cancer vaccine comprising patient-derived dendritic cells exposed to ERBB2 (HER2)-derived peptides, which potentially enhances anti-tumor immune response against ERBB2 (HER2)-expressing tumor cells (NCI Drug Dictionary).
HLD-0915 HLD0915|HLD 0915 Limited information is currently available on HLD-0915, a putative AR-targeting therapy (Feb 2025).
HLX-1502 HLX 1502|HLX1502|nitroxoline Antibiotic Antineoplastic 2 HLX-1502 is a quinoline antibiotic, which potentially inhibits proliferation of tumor cells with a loss of NF1 (NCI Thesaurus).
HRS-3802 HRS 3802|HRS3802 Limited information is currently available on HRS-3802, a putative CDK inhibitor (Aug 2025).
HRS-5041 HRS 5041|HRS5041 Hormone - Anti-androgens 57 Limited information is currently available on HRS-5041, a putative proteolysis targeting chimera (PROTAC) targeting the androgen receptor (AR) (Mar 2025).
HS-110 Viagenpumatucel-L|AD100-gp96-Ig-HLA A1 HS-110 (viagenpumatucel-L) is a tumor cell vaccine comprised of irradiated tumor cells expressing recombinant gp96-Ig, which is secreted and induces an immune response to endogenous tumor cells (NCI Drug Dictionary).
HS-20110 HS20110|HS 20110 Limited information is currently available on HS-20110 (Jul 2025).
HTR2 T cells HTR2 T-Cells HER2 (ERBB2) Immune Cell Therapy 9 Limited information is currently available on HTR2 T cells, a putative chimeric antigen receptor (CAR) T-cell therapy targeting ERBB2 (HER2) and TRAIL-R2 (Feb 2024).
HX-044 HX 044|HX044 Limited information is currently available on HX-044 (Oct 2024).
IBI129 IBI 129|IBI-129 CD276 Antibody 21 Limited information is currently available on IBI129, a putative CD276 (B7-H3) antibody-drug conjugate (ADC) (Sep 2023).
IBI130 IBI-130|IBI 130 Limited information is currently available on IBI130 (Jul 2023).
IBI3009 IBI-3009 Limited information is currently available on IBI3009, a putative antibody-drug conjugate (ADC) (Sep 2024).
IBI3020 IBI-3020|IBI 3020 CEACAM5 Antibody 12 Limited information is currently available on IBI3020, a putative antibody-drug conjugate (ADC) targeting CEACAM5 (Apr 2025).
IDE849 IDE-849|IDE 849 DLL3 Antibody 10 Limited information is currently available on IDE849, a putative DLL3-targeted antibody-drug conjugate (ADC) (Sep 2025).
IDOV-Immune Limited information is currently available on IDOV-Immune, a putative oncolytic virus (Apr 2025).
II-11 II11|II 11 PAK1 Inhibitor 11 Limited information is currently available on II-11, a putative PAK1 inhibitor (Apr 2023).
IMC-P115C IMCP115C|IMC P115C Limited information is currently available on IMC-P115C, a putative soluble T-cell receptor (TCR) targeting CD3 and PRAME (Sep 2025).
IMC-R117C IMC R117C|IMCR117C Limited information is currently available on IMC-R117C, a putative bispecific protein targeting CD3 and PIWIL1 (Mar 2025).
IMU-935 IMU 935|IMU935 Limited information is currently available on IMU-935, a putative inverse agonist of the transcription factor RORgamma truncated (Dec 2022).
INBRX-106 INBRX106|INBRX 106|ES 102|ES-102|ES102 OX40 Antibody 15 INBRX-106 (ES 102) is a hexavalent antibody that binds to the TNFRSF4 (OX40) receptor, resulting in clustering and activation of TNFRSF4 (OX40), and potentially leading to activation of immune response and tumor cell killing (NCI Drug Dictionary).
INCB186748 INCB 186748|INCB-186748 KRAS G12D Inhibitor 25 Limited information is currently available on INCB186748, a putative KRAS G12D inhibitor (Apr 2025).
IPN01195 IPN-01195|IPN 01195 Limited information is currently available on IPN01195 (Feb 2025).
IVAC Limited information is currently available on IVAC, a personalized peptide vaccine (June 2023).
IVT-8086 IVT 8086|IVT8086 LImited information is currently available on IVT-8086, a putative anti-SFRP2 (secreted frizzled-related protein 2) antibody (Apr 2023).
JAB-23E73 JAB 23E73|JAB23E73 KRAS Inhibitor 30 Limited information is currently available on JAB-23E73, a putative pan-KRAS inhibitor (May 2025).
JNJ-70218902 JNJ70218902|JNJ 70218902|JNJ-902|JNJ 902|JNJ902 CD3 Antibody 119 JNJ-70218902 is a bispecific antibody targeting TMEFF2-expressing tumor cells and CD3-expressing T-cells, potentially resulting in T-cell-mediated cell death and antitumor activity (NCI Thesaurus, Ann Oncol (2022) 33 (suppl_7): S616-S652).
JNJ-87562761 JNJ 87562761|JNJ87562761 Limited information is currently available on JNJ-87562761 (Dec 2024).
JNJ-88998377 JNJ 88998377|JNJ88998377 Limited information is available on JNJ-88998377 (Aug 2024).
JNJ-89402638 JNJ 89402638|JNJ89402638 CD3 Antibody 119 ENPP3 Antibody 5 Limited information is currently available on JNJ-89402638, a putative bispecific antibody targeting ENPP3 and CD3 (Nov 2024).
JNJ-89862175 JNJ 89862175|JNJ89862175 ENPP3 Antibody 5 Limited information is currently available on JNJ-89862175, a putative antibody-drug conjugate (ADC) targeting ENPP3 (Nov 2025).
JNJ-90009530 JNJ 90009530|JNJ90009530 CD20 Immune Cell Therapy 14 Limited information is currently available on JNJ-90009530, a putative chimeric antigen receptor (CAR) T cell therapy targeting MS4A1 (CD20) (Nov 2023).
JNJ-90189892 JNJ 90189892|JNJ90189892 Limited information is currently available on JNJ-90189892 (Apr 2025).
JNJ-90301900 JNJ90301900|JNJ 90301900 Limited information is currently available on JNJ-90301900 (Nov 2024).
JNJ-95437446 JNJ 95437446|JNJ95437446 Limited information is currently available on JNJ-95437446 (Aug 2025).
JSKN033 JSKN-033|JSKN 033 HER2 (ERBB2) Antibody 79 HER2 (ERBB2) Antibody-Drug Conjugate 35 PD-L1 Inhibitor 15 JSKN033 is a combination of JSKN003, an antibody-drug conjugate (ADC) targeting ERBB2 (HER2), and KN035, a CD274 (PD-L1) inhibitor, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2024;12).
KBA1412 KBA-1412|KBA 1412 Limited information is currently available on KBA1412 (Apr 2023).
KFA115 KFA-115|KFA 115|NVP-KFA115|NVPKFA115|NVP KFA115 Limited information is currently available on KFA115 (May 2023).
KQB168 KQB 168|KQB-168 Limited information is currently available on KQB168 (Jul 2025).
KQB548 KQ-B548|KQ B548|BAY3771249|BAY 3771249|BAY-3771249 KRAS G12D Inhibitor 25 Limited information is currently available on KQB548 (BAY 3771249), a putative KRAS G12D inhibitor (Oct 2025).
KTX-2001 KTX2001|KTX 2001 Limited information is currently available on KTX-2001, a putative NSD2 inhibitor (Aug 2025).
KUR-502 KUR 502|KUR502|CMD 502 CD19 Immune Cell Therapy 72 Limited information is available on KUR-502, a putative cell therapy comprising allogeneic natural killer T-lymohocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023).
LB-LR1109 LB LR1109|LBLR1109 Limited information is currently available on LB-LR1109, a putative anti-LILRB1 monoclonal antibody (Sep 2024).
LM-061 LM 061|LM061 Limited information is currently available on LM-061 (Apr 2023).
LM-299 LM 299|LM299 PD-L1/PD-1 antibody 132 VEGF Antibody 15 Limited information is currently available on LM-299, a putative bispecific antibody targeting PD-1 and VEGF (May 2025).
LTG2950 LTG-2950|LTG 2950 CD19 Immune Cell Therapy 72 CD20 Immune Cell Therapy 14 CD22 Immune Cell Therapy 13 Limited information is currently available on LTG2950, putative T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, CD20, and CD22 (Sep 2025).
LTZ-301 LTZ 301|LTZ301 Limited information is currently available on LTZ-301, a putative myeloid engager immunotherapy (Aug 2025).
LVGN6501 LVGN 6501|LVGN-6501 Limited information is currently available on LVGN6501 (Apr 2023).
LY4257496 LY-4257496|LY 4257496 Limited information is currently available on LY4257496, a putative radioligand therapy targeting GRPR (Aug 2025).
LY4337713 LY-4337713|LY 4337713 Limited information is currently available on LY4337713, a putative radioligand targeting FAP (Oct 2025).
LY4584180 LY-4584180|LY 4584180 Limited information is currently available on LY4584180, a putative BCL6 molecular glue (Nov 2025).
M3T01 M 3T01|M-3T01 Limited information is currently available on M3T01, a putative monoclonal antibody targeting FasL (Dec 2024).
MAQ-001 MAQ001|MAQ 001 Limited information is currently available on MAQ-001 (Jul 2024).
MB-dNPM1-TCR.1 MB-dNPM1TCR.1|MB-dNPM1 TCR.1 Limited information is currently available on MB-dNPM1-TCR.1, a putative HLA-A*02:01-restricted T-cell receptor (TCR) T-cell therapy targeting mutant NPM1 (Sep 2024).
MBF-362 MBF362|MBF 362 Limited information is currently available on MBF-362, a putative EP4 (PTGER4) antagonist (Jul 2023).
MBRC-201 MBRC201|MBRC 201 Limited information is currently available on MBRC-201, a putative antibody-drug conjugate (Sep 2025).
MDX2004 MDX-2004|MDX 2004 CD28 Antibody 12 CD3 Antibody 119 TNFRSF9 Antibody 36 Limited information is currently available on MDX2004, a putative trispecific antibody–fusion protein targeting CD3, CD28, and TNFRSF9 (4-1BB) (Sep 2025).
MEDI9090 MEDI 9090|MEDI-9090 Limited information is currently available on MEDI9090 (Apr 2023).
MEN2501 MEN-2501|MEN 2501 Limited information is currently available on MEN2501, a putative KIF18A inhibitor (Nov 2025).
MK-1088 MK1088|MK 1088 Limited information is currently available on MK-1088 (Apr 2023).
MK-1484 MK 1484|MK1484 Limited information is currently available on MK-1484, a putative IL-2 agonist (Apr 2023).
MK-3120 MK3120|MK 3120|SKB 410|SKB-410|SKB 410 NECTIN4 Antibody 11 Limited information is currently available on MK-3120, a putative antibody-drug conjugate (ADC) targeting Nectin-4 (Apr 2025).
MK-4700 MK 4700|MK4700 Limited information is currently available on MK-4700 (Apr 2025).
MK-6837 MK6837|MK 6837 Limited information is currently available on MK-6837 (Jul 2024).
MK-8294 MK 8294|MK8294|DAB-014236|DAB 014236|DAB014236 Limited information is currently available on MK-8294 (Aug 2025).
MNPR-101-PCTA-177Lu Limited information is currently available on MNPR-101-PCTA-177Lu, a putative radiotherapy targeting PLAUR (uPAR) (Sep 2024).
MPT-0118 MPT0118|MPT 0118 MALT1 Inhibitor 6 MPT-0118 inhibits mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which may result in reprogramming of regulatory T cells, potentially leading to inhibition of tumor growth (Journal for ImmunoTherapy of Cancer 2021; Vol 9, Issue Suppl 2; Annals of Oncology 32 (2021): S857).
MS201408-0005A Limited information is currently available on MS201408-0005A (Apr 2023).
MS201408-0005B Limited information is currently available on MS201408-0005B (Apr 2023).
MS201408-0005C Limited information is currently available on MS201408-0005C (Apr 2023).
MT-601 MT 601|MT601 Limited information is currently available on MT-601, a putative T-cell therapy targeting 6 tumor-associated antigens (Apr 2023).
NDI-219216 NDI 219216|NDI219216 WRN Inhibitor 5 Limited information is currently available on NDI-219216, a putative WRN inhibitor (Mar 2025).
NG101m Limited information is currently available on NG101m (Apr 2023).
NKT5097 NKT-5097|NKT 5097 CDK2/4 Inhibitor 1 Limited information is currently available on NKT5097, a putative dual CDK2/4 degrader (Jun 2025).
NRM-823 NRM823|NRM 823 Limited information is currently available on NRM-823, a putative T-cell engager (Nov 2025).
NT-175 NT175|NT 175 NT-175 comprises autologous T-lymphocytes engineered to express an HLA-A*02:01-restricted T-cell receptor (TCR) targeting TP53 R175H, and to lack expression of TGFBR2, which potentially induces a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing TP53 R175H and inhibits tumor growth (J Clin Oncol 2024 42:16_suppl, 5011, NCI Drug Dictionary).
NTS071 NT S071|NT-S071 p53 Activator 12 Limited information is currently available on NTS071, a putative reactivator of TP53 (Jul 2025).
NUV-868 NUV868|NUV 868 BET Inhibitor (Pan) 33 NUV-868 selectively binds to the BD2 domain of the BRD4 protein, leading to disruption of chromatin remodeling and decreased expression of oncogenes, potentially leading to growth inhibition of tumor cells (NCI Drug Dictionary).
NY-ESO-1 TCR CD4- CD34+ HSC NY-ESO-1 CD4-TCR CD34+ HSC Limited information is currently available on NY-ESO-1 TCR CD4- CD34+ HSC (Apr 2023).
NeoVax Limited information is currently available on NeoVax, a putative peptide personalized tumor vaccine (Apr 2023).
Neoantigen-targeted ppDC Limited information is currently available on neoantigen-targeted ppDC, a putative dendritic cell vaccine (Apr 2024).
ODM-212 ODM212|ODM 212 Limited information is currently available on ODM-212, a putative TEAD inhibitor (Dec 2024).
OKN4395 OKN-4395|OKN 4395 Limited information is currently available on OKN4395, a putative EP2 and EP4 inhibitor (Jan 2025).
ORB-021 ORB 021|ORB021 Limited information is currently available on ORB-021 (Sep 2024).
OSE-279 OSE279|OSE 279 Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 OSE-279 is a monoclonal antibody that targets PDCD1 (PD-1) and inhibits ligand binding, which potentially enhances antitumor immune response (Mol Cancer Ther (2023) 22 (12_Supplement): C063).
OT-A201 OT A201|OTA201 Limited information is currently available on OT-A201 (Jul 2023).
OTS167PO OTS 167PO|OTS-167PO Limited information is currently available on OTS167PO, a putative MELK inhibitor (Apr 2023).
P30-EPS P30EPS|P30 EPS P30-EPS is a peptide vaccine that consist of EphA2, survivin and cytomegalovirus matrix protein pp65 linked to tetanus toxoid epitope P30, which may lead to a cytotoxic T-lymphocyte mediated response against EphA2, CMV pp65 and survivin-expressing tumor cells (NCI Drug Dictionary).
PEP08 PEP-08|PEP 08 PRMT5 Inhibitor 21 Limited information is currently available on PEP08, a putative PRMT5 inhibitor (Sep 2025).
PF-06940434 PF06940434|PF 06940434 PF-06940434 is an integrin alpha v beta 8 antagonist that prevents the activation of TGFB1, leading to an anti-tumor response (Mar 2020).
PF-07225570 PF07225570|PF 07225570 Limited information is currently available on PF-07225570 (Apr 2023).
PF-07329640 PF07329640|PF 07329640 Limited information is currently available on PF-07329640, a putative LTBR agonist antibody (Jun 2024).
PF-08052667 PF08052667|PF 08052667 Limited information is currently available on PF-08052667 (Oct 2025).
PHN-012 PHN012|PHN 012 Limited information is currently available on PHN-012, a putative antibody-drug conjugate (ADC) (Aug 2025).
PT0253 Limited information is currently available on PT0253 (Feb 2025).
PalloV-CC Limited information is currently available on PalloV-CC, a putative cancer vaccine (Apr 2023).
Peptide vaccine IPX Limited information is currently available on Peptide vaccine IPX, a putative personalized peptide vaccine (Nov 2023).
QEQ278 QEQ 278|QEQ-278 Limited information is currently available on QEQ278 (Jan 2023).
RC198 RC-198|RC 198 Limited information is currently available on RC198 (Jun 2023).
REGN4336 REGN-4336|REGN 4336 CD3 Antibody 119 PSMA Antibody 22 REGN4336 is a a bispecific antibody that targets prostate-specific membrane antigen (PSMA) expressed on tumor cells and the CD3 antigen expressed on T-lymphocytes, potentially leading to activation and recruitment of cytotoxic T-lymphocytes (CTL) to tumor cells expressing PSMA and CTL-mediated tumor cell killing (NCI Drug Dictionary).
RM-007 RM007|RM 007 KRAS Inhibitor 30 Limited information is currently available on RM-007, a putative Kras inhibitor (Apr 2023).
RM-008 RM008|RM 008 KRAS Inhibitor 30 Limited information is currently available on RM-008, a putative Kras inhibitor (Apr 2023).
RM-1995 RM 1995|RM1995 RM-1995 is an antibody-dye conjugate comprised of an anti-CD35 monoclonal antibody (Basiliximab) linked to the dye IR700, which may result in activation of the cytotoxic T-lymphocyte mediated antitumor immune response (NCI Drug Dictionary).
RNK08954 RNK 08954|RNK-08954 Limited information is currently available on RNK08954 (Nov 2024).
RO7296682 RO-7296682|RO 7296682 RO7296682 is a monoclonal antibody that recognizes CD25 (IL-2R alpha) on regulatory T lymphocytes (Tregs), potentially leading to Treg depletion and increased anti-tumor immune response (NCI Drug Dictionary)
RO7566802 RO-7566802|RO 7566802 Limited information is currently available on RO7566802 (Nov 2023).
RO7567132 RO 7567132|RO-7567132 Limited information is currently available on RO7567132 (Sep 2024).
RO7673396 RO-7673396|RO 7673396 RAS Inhibitor (Pan) 13 Limited information is currently available on RO7673396, a putative Ras inhibitor (Apr 2025).
RO7759065 RO-7759065|RO 7759065 Limited information is currently available on RO7759065 (Aug 2024).
RPCAR01 RPCAR-01|RPCAR 01 GPC3 Immune Cell Therapy 8 Limited information is currently available on RPCAR01, a putative T-cell therapy targeting GPC3 (Jun 2025).
RR001 RR-001|RR 001 Limited information is currently available on RR001, a putative cell therapy comprising autologous adipose perivascular stromal cells engineered to secrete soluble tumor necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL) (Mar 2025).
S095029 S-095029|S 095029|Sym 025|Sym-025|Sym025 NKG2A Antibody 4 S095029 is a monoclonal antibody that targets natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), which may result in an antitumor immune response mediated by NK cells and cytotoxic T-lymphocytes (NCI Drug Dictionary).
SBO-154 SBO154|SBO 154 MUC1 Antibody 8 Limited information is currently available on SBO-154, a putative antibody-drug conjugate (ADC) targeting MUC1 (Jul 2025).
SDGR5 SOS1 Inhibitor 17 Limited information is currently available on SDGR5, a putative SOS1 inhibitor (Apr 2023).
SG2501 SG-2501|SG 2501 Limited information is currently available on SG2501 (Apr 2023).
SIM0505 SIM 0505|SIM-0505 Limited information is currently available on SIM0505, a putative antibody-drug conjugate (ADC) targeting CDH6 (Sep 2025).
SL-901 SL901|SL 901 PI3K Inhibitor (Pan) 42 Limited information is currently available on SL-901, a putative inhibitor of PI3K alpha and delta, and PIK3C2 beta (Apr 2023).
SLV-154 SLV154|SLV 154 Limited information is currently available on SLV-154 (May 2025).
SLV-324 SLV324|SLV 324 Limited information is currently available on SLV-324, a putative antibody-drug conjugate (ADC) (Aug 2025).
SPYK04 SPYK 04|SPYK-04 Limited information is currently available on SPYK04 (Apr 2023).
SQZ-AAC-HPV Engineered AAC Loaded with HPV16 Epitopes SQZ-AAC-HPV is a cell therapy comprised of autologous red blood cells engineered to express tumor-specific antigens (TAA) and human papillomavirus (HPV) type 16 epitopes and carrying a Toll-like receptor (TLR) agonist as an adjuvant, with potential to induce an anti-tumor immune response against HPV16- or TAA-expressing tumor cells (NCI Drug Dictionary).
SSGJ-709 SSGJ 709|SSGJ709 LAG3 Antibody 19 PD-L1/PD-1 antibody 132 Limited information is currently available on SSGJ-709, a putative bispecific antibody targeting CD274 (PD-L1) and LAG3 (Jun 2025).
ST-01156 ST01156|ST 01156 Limited information is currently available on ST-01156, a putative RBM39 degrader (Oct 2025).
STIL101 STIL-101|STIL 101 Limited information is currently available on STIL101, a putative autologous T-cell therapy (Oct 2024).
SV-102 SV102|SV 102 Limited information is currently available on SV102, a putative multi-target biologic therapy (Jan 2025).
SY-2101 SY 2101|SY2101 Limited information is currently available on SY-2101, a putative form of Arsenic Trioxide (Apr 2023).
SynKIR-310 SynKIR 310|SynKIR310 CD19 Immune Cell Therapy 72 Limited information is currently available on SynKIR-310, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (Nov 2024).
TAK-188 TAK188|TAK 188 CCR8 Antibody 13 Limited information is currently available on TAK-188, a putative antibody-drug conjugate (ADC) targeting CCR8 (Oct 2025).
TBI-2001 TBI 2001|TBI2001 CD19 Immune Cell Therapy 72 Limited information is currently available on TBI-2001, a putative cell therapy comprising T-lymphocytes expressing a chimeric antigen receptor (CAR) targeting CD19 (Nov 2023).
TBio-6517 RIVAL-01 TBio-6517 is an engineered vaccinia virus that expresses the Flt3 ligand, an antibody targeting CTLA4, and the cytokine IL-12, which may lead to immune activation and increased anti-tumor immune response, and decreased tumor cell proliferation (NCI Drug Dictionary).
TCRT-ESO-A2 Limited information is currently available on TCRT-ESO-A2, a putative T-cell receptor (TCR) cell therapy targeting NY-ESO-1 (Apr 2023).
TEIPP24 LRPAP7-30V-SLP vaccine Limited information is currently available for TEIPP24, a putative synthetic long peptide vaccine (Jan 2024).
TER-2013 TER2013|TER 2013 Limited information is currently available on TER-2013 (Aug 2025).
TGN-S11 TGN S11|TGNS11 TGN-S11 is an anti-viral agent with potential antitumor activity (NCI Drug Dictionary).
TLN-121 TLN121|TLN 121 Limited information is currently available on TLN-121 (Jul 2025).
TLN-254 TLN 254|TLN254 Limited information is currently available on TLN-254 (Dec 2024).
TLN-372 TLN372|TLN 372 KRAS Inhibitor 30 Limited information is currently available on TLN-372, a putative pan-KRAS inhibitor (Oct 2025).
TP-1454 TP1454|TP 1454 TP-1454 is a pyruvate kinase M2 (PKM2) activator, which may inhibit tumor cell viability and tumor growth, and enhance anti-tumor immune response in combination with other agents (Mol Cancer Ther December 1 2019 (18) (12 Supplement) B080).
TRPH 011 TRPH011|TRPH-011 VEGFR2 Antibody 4 Limited information is currently available on TRPH 011, a putative human bispecific antibody targeting vascular endothelial growth factor receptor 2 (KDR) and tyrosine kinase receptor 2 (Tie2) (c).
TSC-201-B0702 TSC 201-B0702|TSC201-B0702 Limited information is currently available on TSC-201-B0702, a putative T-cell receptor (TCR) therapy targeting MAGE-C2 presented on HLA-B*07:02 (Jun 2024).
TSC-204-A0101 TSC 204-A0101|TSC204-A0101 Limited information is currently available on TSC-204-A0101, a putative T-cell receptor (TCR) therapy targeting MAGE-A1 presented on HLA-A*01:01 (Jun 2024).
Tarcidomgen kimleucel FCTX-CL19-1|FCTX CL19-1|FCTXCL19-1 CD19 Immune Cell Therapy 72 Limited information is currently available on Tarcidomgen kimleucel, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (Jan 2024).
VERT-002 VERT002|VERT 002|PFL-002|PFL002|PFL 002 MET Antibody 37 Limited information is currently available on VERT-002, a putative monoclonal antibody targeting MET (Nov 2024).
VIR-5525 AMX-525|AMX525|AMX 525|VIR 5525|VIR5525 EGFR Antibody 72 Limited information is currently available on VIR-5525, a putative T-cell engager targeting EGFR (May 2025).
VLPONC-01 VLPONC 01|VLPONC01|VRP-encapsulated saRNA encoding IL-12 Limited information is currently available on VLPONC-01, a putative viral replicon particle engineered to express IL-12 (Mar 2025).
VVD-159642 VVD 159642|VVD159642 PIK3CA inhibitor 27 RAS Inhibitor (Pan) 13 Limited information is currently available on VVD-159642, a putative inhibitor of Ras and Pi3kalpha (Mar 2025).
WEF-001 WEF001|WEF 001 Limited information is currently available on WEF-001 (Sep 2025).
X4P-001 Mavorixafor|X4P-001-IO|AMD-070|AMD-11070|AMD11070 CXCR4 Inhibitor 15 Mavorixafor (X4P-001), is a CXCR4 antagonist, which blocks the binding of CXCL12 to prevent metastasis and may activate cytotoxic T-lymphocytes (PMID: 23538388).
iTCR-transduced PBL Individual Patient TCR-Transduced PBL Limited information is currently available on iTCR-transduced PBL, putative autologous T-lymphocytes engineered to express T-cell receptors against patient-specific neoantigens (Apr 2023).
mRNA plus lysate-loaded dendritic cell vaccine Limited information is currently available on mRNA plus lysate-loaded dendritic cell vaccine, a putative autologous dendritic cell vaccine loaded with mRNA and tumor lysate (Jul 2023).
mRNA-2736 mRNA2736|mRNA 2736 Limited information is currently available on mRNA-2736 (Jul 2023).
mRNA-2808 mRNA 2808|mRNA2808 Limited information is currently available on mRNA-2808 (Aug 2025).
mRNA-4106 mRNA4106|mRNA 4106 Limited information is currently available on mRNA-4106 (Mar 2025).
mRNA-4203 mRNA4203|mRNA 4203 Limited information is currently available on mRNA-4203 (Aug 2025).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
ABL1 act mut unknown gain of function ABL1 act mut indicates that this variant results in a gain of function in the Abl1 protein. However, the specific amino acid change has not been identified.
ABL1 amp none no effect ABL1 amplification indicates an increased number of copies of the ABL1 gene. However, the mechanism causing the increase is unspecified.
ABL1 fusion fusion unknown ABL1 fusion indicates a fusion of the ABL1 gene, but the fusion partner is unknown.
ABL1 inact mut unknown loss of function ABL1 inact mut indicates that this variant results in a loss of function of the Abl1 protein. However, the specific amino acid change has not been identified.
ABL1 mutant unknown unknown ABL1 mutant indicates an unspecified mutation in the ABL1 gene.
ABL1 over exp none no effect ABL1 over exp indicates an over expression of the Abl1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
ABL1 rearrange unknown unknown ABL1 rearrangement indicates an unspecified rearrangement of the ABL1 gene.
ABL1 wild-type none no effect Wild-type ABL1 indicates that no mutation has been detected within the ABL1 gene.
ALK act mut unknown gain of function ALK act mut indicates that this variant results in a gain of function in the Alk protein. However, the specific amino acid change has not been identified.
ALK amp none no effect ALK amplification indicates an increased number of copies of the ALK gene. However, the mechanism causing the increase is unspecified.
ALK del exon2 deletion unknown ALK del exon2 indicates a deletion of exon 2 of the ALK gene.
ALK del exon2-17 deletion unknown ALK del exon2-17 indicates the deletion of exons 2-17 of the ALK gene.
ALK del exon2-19 deletion unknown ALK del exon2-19 indicates the deletion of exons 2-19 of the ALK gene.
ALK del exon2-3 deletion unknown ALK del exon2-3 indicates the deletion of exons 2-3 of the ALK gene.
ALK del exon3 deletion unknown ALK del exon3 indicates a deletion of exon 3 of the ALK gene.
ALK F1174X missense unknown ALK F1174X indicates any Alk missense mutation that results in replacement of the phenylalanine (F) at amino acid 1174 by a different amino acid.
ALK F1245X missense unknown ALK F1245X indicates any Alk missense mutation that results in replacement of the phenylalanine (F) at amino acid 1245 by a different amino acid.
ALK fusion fusion unknown ALK fusion indicates a fusion of the ALK gene, but the fusion partner is unknown.
ALK G1202X missense unknown ALK G1202X indicates any ALK missense mutation that results in replacement of the glycine (G) at amino acid 1202 by a different amino acid.
ALK I1171X missense unknown ALK I1171X indicates any Alk missense mutation that results in replacement of the isoleucine (I) at amino acid 1171 by a different amino acid.
ALK inact mut unknown loss of function ALK inact mut indicates that this variant results in a loss of function of the Alk protein. However, the specific amino acid change has not been identified.
ALK L1196X missense unknown ALK L1196X indicates any Alk missense mutation that results in replacement of the leucine (L) at amino acid 1196 by a different amino acid.
ALK L1198X missense unknown ALK L1198X indicates any Alk missense mutation that results in replacement of the leucine (L) at amino acid 1198 by a different amino acid.
ALK mutant unknown unknown ALK mutant indicates an unspecified mutation in the ALK gene.
ALK negative unknown loss of function ALK negative indicates a lack of expression of the ALK mRNA and/or protein.
ALK over exp none no effect ALK over exp indicates an over expression of the Alk protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
ALK positive unknown unknown ALK positive indicates the presence of ALK mRNA and/or protein. ALK positive has been used alternatively to refer to presence of an ALK fusion or rearrangement. For related data, refer to ALK fusion or ALK rearrange in CKB.
ALK R1275X missense unknown ALK R1275X indicates any Alk missense mutation that results in replacement of the arginine (R) at amino acid 1275 by a different amino acid.
ALK rearrange unknown unknown ALK rearrangement indicates an unspecified rearrangement of the ALK gene.
ALK V1180X missense unknown ALK V1180X indicates any Alk missense mutation that results in replacement of the valine (V) at amino acid 1180 by a different amino acid.
ALK wild-type none no effect Wild-type ALK indicates that no mutation has been detected within the ALK gene.
APC dec exp none no effect APC dec exp indicates decreased expression of the Apc protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
APC inact mut unknown loss of function APC inact mut indicates that this variant results in a loss of function of the Apc protein. However, the specific amino acid change has not been identified.
APC LOH deletion unknown APC LOH indicates the loss of one parental copy of the APC gene, resulting in loss of heterozygosity.
APC mutant unknown unknown APC mutant indicates an unspecified mutation in the APC gene.
APC wild-type none no effect Wild-type APC indicates that no mutation has been detected within the APC gene.
ARID1B dec exp none no effect ARID1B dec exp indicates decreased expression of the Arid1b protein. However, the mechanism causing the decreased expression is unspecified.
ARID1B inact mut unknown loss of function ARID1B inact mut indicates that this variant results in a loss of function of the Arid1b protein. However, the specific amino acid change has not been identified.
ARID1B mutant unknown unknown ARID1B mutant indicates an unspecified mutation in the ARID1B gene.
ARID1B wild-type none no effect Wild-type ARID1B indicates that no mutation has been detected within the ARID1B gene.
ARID2 del deletion loss of function ARID2 del indicates a deletion of the ARID2 gene.
ARID2 inact mut unknown loss of function ARID2 inact mut indicates that this variant results in a loss of function of the Arid2 protein. However, the specific amino acid change has not been identified.
ARID2 mutant unknown unknown ARID2 mutant indicates an unspecified mutation in the ARID2 gene.
ARID2 wild-type none no effect Wild-type ARID2 indicates that no mutation has been detected within the ARID2 gene.
ATM amp none no effect ATM amplification indicates an increased number of copies of the ATM gene. However, the mechanism causing the increase is unspecified.
ATM dec exp none no effect ATM dec exp indicates decreased expression of the Atm protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
ATM del deletion loss of function ATM del indicates a deletion of the ATM gene.
ATM inact mut unknown loss of function ATM inact mut indicates that this variant results in a loss of function of the Atm protein. However, the specific amino acid change has not been identified.
ATM LOH deletion unknown ATM LOH indicates the loss of one parental copy of the ATM gene, resulting in loss of heterozygosity.
ATM loss unknown loss of function ATM loss indicates loss of the ATM gene, mRNA, and protein.
ATM mutant unknown unknown ATM mutant indicates an unspecified mutation in the ATM gene.
ATM negative unknown loss of function ATM negative indicates a lack of expression of the ATM mRNA and/or protein.
ATM over exp none no effect ATM over exp indicates an over expression of the Atm protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
ATM positive unknown unknown ATM positive indicates the presence of ATM mRNA and/or protein.
ATM R3008X missense unknown ATM R3008X indicates any ATM missense mutation that results in replacement of the arginine (R) at amino acid 3008 by a different amino acid.
ATM R337X missense unknown ATM R337X indicates any ATM missense mutation that results in replacement of the arginine (R) at amino acid 337 by a different amino acid.
ATM wild-type none no effect Wild-type ATM indicates that no mutation has been detected within the ATM gene.
ATR amp none no effect ATR amplification indicates an increased number of copies of the ATR gene. However, the mechanism causing the increase is unspecified.
ATR dec exp none no effect ATR dec exp indicates decreased expression of the Atr protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
ATR del deletion loss of function ATR del indicates a deletion of the ATR gene.
ATR inact mut unknown loss of function ATR inact mut indicates that this variant results in a loss of function of the Atr protein. However, the specific amino acid change has not been identified.
ATR mutant unknown unknown ATR mutant indicates an unspecified mutation in the ATR gene.
ATR over exp none no effect ATR over exp indicates an over expression of the Atr protein. However, the mechanism causing the over expression is unspecified.
ATR positive unknown unknown ATR positive indicates the presence of ATR mRNA and/or protein.
ATR wild-type none no effect Wild-type ATR indicates that no mutation has been detected within the ATR gene.
BRAF A598X missense unknown BRAF A598X indicates any BRAF missense mutation that results in replacement of the alanine (A) at amino acid 598 by a different amino acid.
BRAF act mut unknown gain of function BRAF act mut indicates that this variant results in a gain of function in the Braf protein. However, the specific amino acid change has not been identified.
BRAF amp none no effect BRAF amplification indicates an increased number of copies of the BRAF gene. However, the mechanism causing the increase is unspecified.
BRAF D594X missense unknown BRAF D594X indicates any BRAF missense mutation that results in replacement of the aspartic acid (D) at amino acid 594 by a different amino acid.
BRAF dec exp none no effect BRAF dec exp indicates decreased expression of the Braf protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
BRAF E586X missense unknown BRAF E586X indicates any BRAF missense mutation that results in replacement of the glutamic acid (E) at amino acid 586 by a different amino acid.
BRAF F595X missense unknown BRAF F595X indicates any BRAF missense mutation that results in replacement of the phenylalanine (F) at amino acid 595 by a different amino acid.
BRAF fusion fusion unknown BRAF fusion indicates a fusion of the BRAF gene, but the fusion partner is unknown.
BRAF G464X missense unknown BRAF G464X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 464 by a different amino acid.
BRAF G466X missense unknown BRAF G466X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 466 by a different amino acid.
BRAF G469X missense unknown BRAF G469X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 469 by a different amino acid.
BRAF G596X missense unknown BRAF G596X indicates any BRAF missense mutation that results in replacement of the glycine (G) at amino acid 596 by a different amino acid.
BRAF I463X missense unknown BRAF I463X indicates any BRAF missense mutation that results in replacement of the isoleucine (I) at amino acid 463 by a different amino acid.
BRAF inact mut unknown loss of function BRAF inact mut indicates that this variant results in a loss of function of the Braf protein. However, the specific amino acid change has not been identified.
BRAF K601X missense unknown BRAF K601X indicates any BRAF missense mutation that results in replacement of the lysine (K) at amino acid 601 by a different amino acid.
BRAF L485X missense unknown BRAF L485X indicates any BRAF missense mutation that results in replacement of the leucine (L) at amino acid 485 by a different amino acid.
BRAF L597X missense unknown BRAF L597X indicates any BRAF missense mutation that results in replacement of the leucine (L) at amino acid 597 by a different amino acid.
BRAF loss unknown loss of function BRAF loss indicates loss of the BRAF gene, mRNA, and protein.
BRAF mutant unknown unknown BRAF mutant indicates an unspecified mutation in the BRAF gene.
BRAF N581X missense unknown BRAF N581X indicates any BRAF missense mutation that results in replacement of the asparagine (N) at amino acid 581 by a different amino acid.
BRAF over exp none no effect BRAF over exp indicates an over expression of the Braf protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
BRAF P367X missense unknown BRAF P367X indicates any BRAF missense mutation that results in replacement of the proline (P) at amino acid 367 by a different amino acid.
BRAF Q257X missense unknown BRAF Q257X indicates any BRAF missense mutation that results in replacement of the glutamine (Q) at amino acid 257 by a different amino acid.
BRAF R462X missense unknown BRAF R462X indicates any BRAF missense mutation that results in replacement of the arginine (R) at amino acid 462 by a different amino acid.
BRAF rearrange unknown unknown BRAF rearrangement indicates an unspecified rearrangement of the BRAF gene.
BRAF S467X missense unknown BRAF S467X indicates any BRAF missense mutation that results in replacement of the serine (S) at amino acid 467 by a different amino acid.
BRAF T241X missense unknown BRAF T241X indicates any BRAF missense mutation that results in replacement of the threonine (T) at amino acid 241 by a different amino acid.
BRAF T599X missense unknown BRAF T599X indicates any BRAF missense mutation that results in replacement of the threonine (T) at amino acid 599 by a different amino acid.
BRAF V600X missense unknown BRAF V600X indicates any BRAF missense mutation that results in replacement of the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987).
BRAF wild-type none no effect Wild-type BRAF indicates that no mutation has been detected within the BRAF gene.
CBL act mut unknown gain of function CBL act mut indicates that this variant results in a gain of function in the Cbl protein. However, the specific amino acid change has not been identified.
CBL dec exp none no effect CBL dec exp indicates decreased expression of the Cbl protein. However, the mechanism causing the decreased expression is unspecified.
CBL del deletion loss of function CBL del indicates a deletion of the CBL gene.
CBL exon8 unknown unknown CBL exon 8 indicates an unspecified mutation has occurred in exon 8 of the CBL gene.
CBL exon9 unknown unknown CBL exon 9 indicates an unspecified mutation has occurred in exon 9 of the CBL gene.
CBL inact mut unknown loss of function CBL inact mut indicates that this variant results in a loss of function of the Cbl protein. However, the specific amino acid change has not been identified.
CBL LOH deletion unknown CBL LOH indicates the loss of one parental copy of the CBL gene, resulting in loss of heterozygosity.
CBL loss unknown loss of function CBL loss indicates loss of the CBL gene, mRNA, and protein.
CBL mutant unknown unknown CBL mutant indicates an unspecified mutation in the CBL gene.
CBL wild-type none no effect Wild-type CBL indicates that no mutation has been detected within the CBL gene.
CDKN2A amp none no effect CDKN2A amplification indicates an increased number of copies of the CDKN2A gene. However, the mechanism causing the increase is unspecified.
CDKN2A dec exp none no effect CDKN2A dec exp indicates decreased expression of the Cdkn2a protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
CDKN2A del deletion loss of function CDKN2A del indicates a deletion of the CDKN2A gene.
CDKN2A del exon1-2 deletion unknown CDKN2A del exon1-2 indicates the deletion of exons 1-2 of the CDKN2A gene.
CDKN2A hypermethylation unknown unknown CDKN2A hypermethylation indicates an increased methylation of the CDKN2A gene. However, the mechanism causing the hypermethylation is unspecified.
CDKN2A inact mut unknown loss of function CDKN2A inact mut indicates that this variant results in a loss of function of the Cdkn2a protein. However, the specific amino acid change has not been identified.
CDKN2A LOH deletion unknown CDKN2A LOH indicates the loss of one parental copy of the CDKN2A gene, resulting in loss of heterozygosity.
CDKN2A loss unknown loss of function CDKN2A loss indicates loss of the CDKN2A gene, mRNA, and protein.
CDKN2A mutant unknown unknown CDKN2A mutant indicates an unspecified mutation in the CDKN2A gene.
CDKN2A negative unknown loss of function CDKN2A negative indicates a lack of expression of the CDKN2A mRNA and/or protein.
CDKN2A over exp none no effect CDKN2A over exp indicates an over expression of the Cdkn2a protein. However, the mechanism causing the over expression is unspecified.
CDKN2A positive unknown unknown CDKN2A positive indicates the presence of CDKN2A mRNA and/or protein.
CDKN2A rearrange unknown unknown CDKN2A rearrange indicates an unspecified rearrangement of the CDKN2A gene.
CDKN2A wild-type none no effect Wild-type CDKN2A indicates that no mutation has been detected within the CDKN2A gene.
CHEK1 act mut unknown gain of function CHEK1 act mut indicates that this variant results in a gain of function in the Chek1 protein. However, the specific amino acid change has not been identified.
CHEK1 del deletion loss of function CHEK1 del indicates a deletion of the CHEK1 gene.
CHEK1 inact mut unknown loss of function CHEK1 inact mut indicates that this variant results in a loss of function of the Chek1 protein. However, the specific amino acid change has not been identified.
CHEK1 mutant unknown unknown CHEK1 mutant indicates an unspecified mutation in the CHEK1 gene.
CHEK1 over exp none no effect CHEK1 over exp indicates an over expression of the Chek1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
CHEK1 positive unknown unknown CHEK1 positive indicates the presence of CHEK1 mRNA and/or protein.
CHEK2 amp none no effect CHEK2 amplification indicates an increased number of copies of the CHEK2 gene. However, the mechanism causing the increase is unspecified.
CHEK2 dec exp none no effect CHEK2 dec exp indicates decreased expression of the Chek2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
CHEK2 del deletion loss of function CHEK2 del indicates a deletion of the CHEK2 gene.
CHEK2 inact mut unknown loss of function CHEK2 inact mut indicates that this variant results in a loss of function of the Chek2 protein. However, the specific amino acid change has not been identified.
CHEK2 loss unknown loss of function CHEK2 loss indicates loss of the CHEK2 gene, mRNA, and protein.
CHEK2 mutant unknown unknown CHEK2 mutant indicates an unspecified mutation in the CHEK2 gene.
CHEK2 over exp none no effect CHEK2 over exp indicates an over expression of the Chek2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
CHEK2 wild-type none no effect Wild-type CHEK2 indicates that no mutation has been detected within the CHEK2 gene.
CSF3R act mut unknown gain of function CSF3R act mut indicates that this variant results in a gain of function in the Csf3r protein. However, the specific amino acid change has not been identified.
CSF3R inact mut unknown loss of function CSF3R inact mut indicates that this variant results in a loss of function of the Csf3r protein. However, the specific amino acid change has not been identified.
CSF3R mutant unknown unknown CSF3R mutant indicates an unspecified mutation in the CSF3R gene.
CSF3R wild-type none no effect Wild-type CSF3R indicates that no mutation has been detected within the CSF3R gene.
CTNNB1 act mut unknown gain of function CTNNB1 act mut indicates that this variant results in a gain of function in the Ctnnb1 protein. However, the specific amino acid change has not been identified.
CTNNB1 amp none no effect CTNNB1 amplification indicates an increased number of copies of the CTNNB1 gene. However, the mechanism causing the increase is unspecified.
CTNNB1 dec exp none no effect CTNNB1 dec exp indicates decreased expression of the Ctnnb1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
CTNNB1 del exon3-4 deletion unknown CTNNB1 del exon3-4 indicates the deletion of exons 3-4 of the CTNNB1 gene.
CTNNB1 inact mut unknown loss of function CTNNB1 inact mut indicates that this variant results in a loss of function of the Ctnnb1 protein. However, the specific amino acid change has not been identified.
CTNNB1 mutant unknown unknown CTNNB1 mutant indicates an unspecified mutation in the CTNNB1 gene.
CTNNB1 over exp none no effect CTNNB1 over exp indicates an over expression of the Ctnnb1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
CTNNB1 wild-type none no effect Wild-type CTNNB1 indicates that no mutation has been detected within the CTNNB1 gene.
DNMT3A act mut unknown gain of function DNMT3A act mut indicates that this variant results in a gain of function in the Dnmt3a protein. However, the specific amino acid change has not been identified.
DNMT3A amp none no effect DNMT3A amplification indicates an increased number of copies of the DNMT3A gene. However, the mechanism causing the increase is unspecified.
DNMT3A del deletion loss of function DNMT3A del indicates a deletion of the DNMT3A gene.
DNMT3A inact mut unknown loss of function DNMT3A inact mut indicates that this variant results in a loss of function of the Dnmt3a protein. However, the specific amino acid change has not been identified.
DNMT3A loss unknown loss of function DNMT3A loss indicates loss of the DNMT3A gene, mRNA, and protein.
DNMT3A mutant unknown unknown DNMT3A mutant indicates an unspecified mutation in the DNMT3A gene.
DNMT3A over exp none no effect DNMT3A over exp indicates an over expression of the Dnmt3a protein. However, the mechanism causing the over expression is unspecified.
DNMT3A wild-type none no effect Wild-type DNMT3A indicates that no mutation has been detected within the DNMT3A gene.
EML4 fusion fusion unknown EML4 fusion indicates a fusion of the EML4 gene, but the fusion partner is unknown.
EML4 inact mut unknown loss of function EML4 inact mut indicates that this variant results in a loss of function of the Eml4 protein. However, the specific amino acid change has not been identified.
EML4 mutant unknown unknown EML4 mutant indicates an unspecified mutation in the EML4 gene.
EML4 wild-type none no effect Wild-type EML4 indicates that no mutation has been detected within the EML4 gene.
FBXW7 del deletion loss of function FBXW7 del indicates a deletion of the FBXW7 gene.
FBXW7 inact mut unknown loss of function FBXW7 inact mut indicates that this variant results in a loss of function of the Fbxw7 protein. However, the specific amino acid change has not been identified.
FBXW7 loss unknown loss of function FBXW7 loss indicates loss of the Fbxw7 gene, mRNA, and protein.
FBXW7 mutant unknown unknown FBXW7 mutant indicates an unspecified mutation in the FBXW7 gene.
FBXW7 positive unknown unknown FBXW7 positive indicates the presence of FBXW7 mRNA and/or protein.
FBXW7 wild-type none no effect Wild-type FBXW7 indicates that no mutation has been detected within the FBXW7 gene.
FGFR1 act mut unknown gain of function FGFR1 act mut indicates that this variant results in a gain of function in the Fgfr1 protein. However, the specific amino acid change has not been identified.
FGFR1 amp none no effect FGFR1 amplification indicates an increased number of copies of the FGFR1 gene. However, the mechanism causing the increase is unspecified.
FGFR1 dec exp none no effect FGFR1 dec exp indicates decreased expression of the Fgfr1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
FGFR1 fusion fusion unknown FGFR1 fusion indicates a fusion of the FGFR1 gene, but the fusion partner is unknown.
FGFR1 inact mut unknown loss of function FGFR1 inact mut indicates that this variant results in a loss of function of the Fgfr1 protein. However, the specific amino acid change has not been identified.
FGFR1 mutant unknown unknown FGFR1 mutant indicates an unspecified mutation in the FGFR1 gene.
FGFR1 over exp none no effect FGFR1 over exp indicates an over expression of the FGFR1 protein. However, the mechanism causing the over expression is unspecified.
FGFR1 positive unknown unknown FGFR1 positive indicates the presence of FGFR1 mRNA and/or protein.
FGFR1 rearrange unknown unknown FGFR1 rearrangement indicates an unspecified rearrangement of the FGFR1 gene.
FGFR1 wild-type none no effect Wild-type FGFR1 indicates that no mutation has been detected within the FGFR1 gene.
FGFR2 act mut unknown gain of function FGFR2 act mut indicates that this variant results in a gain of function in the Fgfr2 protein. However, the specific amino acid change has not been identified.
FGFR2 amp none no effect FGFR2 amp indicates an increased number of copies of the FGFR2 gene. However, the mechanism causing the increase is unspecified.
FGFR2 dec exp none no effect FGFR2 dec exp indicates decreased expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
FGFR2 del exon5 deletion unknown FGFR2 del exon5 indicates a deletion of exon 5 of the FGFR2 gene.
FGFR2 del exon7 deletion unknown FGFR2 del exon7 indicates a deletion of exon 7 of the FGFR2 gene.
FGFR2 dup exon9-17 duplication unknown FGFR2 dup exon9-17 indicates a tandem duplication of exons 9-17 of the FGFR2 gene.
FGFR2 exon5 unknown unknown FGFR2 exon 5 indicates an unspecified mutation has occurred in exon 5 of the FGFR2 gene.
FGFR2 exon7 unknown unknown FGFR2 exon 7 indicates an unspecified mutation has occurred in exon 7 of the FGFR2 gene.
FGFR2 fusion fusion unknown FGFR2 fusion indicates a fusion of the FGFR2 gene, but the fusion partner is unknown.
FGFR2 inact mut unknown loss of function FGFR2 inact mut indicates that this variant results in a loss of function of the Fgfr2 protein. However, the specific amino acid change has not been identified.
FGFR2 mutant unknown unknown FGFR2 mutant indicates an unspecified mutation in the FGFR2 gene.
FGFR2 over exp none no effect FGFR2 over exp indicates an over expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
FGFR2 positive unknown unknown FGFR2 positive indicates the presence of FGFR2 mRNA and/or protein.
FGFR2 rearrange unknown unknown FGFR2 rearrangement indicates an unspecified rearrangement of the FGFR2 gene.
FGFR2 wild-type none no effect Wild-type FGFR2 indicates that no mutation has been detected within the FGFR2 gene.
FGFR3 act mut unknown gain of function FGFR3 act mut indicates that this variant results in a gain of function in the Fgfr3 protein. However, the specific amino acid change has not been identified.
FGFR3 amp none no effect FGFR3 amp indicates an increased number of copies of the FGFR3 gene. However, the mechanism causing the increase is unspecified.
FGFR3 dec exp none no effect FGFR3 dec exp indicates decreased expression of the Fgfr3 protein. However, the mechanism causing the decreased expression is unspecified.
FGFR3 fusion fusion unknown FGFR3 fusion indicates a fusion of the FGFR3 gene, but the fusion partner is unknown.
FGFR3 inact mut unknown loss of function FGFR3 inact mut indicates that this variant results in a loss of function of the Fgfr3 protein. However, the specific amino acid change has not been identified.
FGFR3 mutant unknown unknown FGFR3 mutant indicates an unspecified mutation in the FGFR3 gene.
FGFR3 over exp none no effect FGFR3 over exp indicates an over expression of the Fgfr3 protein. However, the mechanism causing the over expression is unspecified.
FGFR3 positive unknown unknown FGFR3 positive indicates the presence of FGFR3 mRNA and/or protein.
FGFR3 rearrange unknown unknown FGFR3 rearrangement indicates an unspecified rearrangement of the FGFR3 gene.
FGFR3 wild-type none no effect Wild-type FGFR3 indicates that no mutation has been detected within the FGFR3 gene.
FLT3 act mut unknown gain of function FLT3 act mut indicates that this variant results in a gain of function in the Flt3 protein. However, the specific amino acid change has not been identified.
FLT3 amp none no effect FLT3 amplification indicates an increased number of copies of the FLT3 gene. However, the mechanism causing the increase is unspecified.
FLT3 exon14 unknown unknown FLT3 exon 14 indicates an unspecified mutation has occurred in exon 14 of the FLT3 gene.
FLT3 exon15 unknown unknown FLT3 exon 15, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 15 of the FLT3 gene.
FLT3 exon16 unknown unknown FLT3 exon 16, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 16 of the FLT3 gene.
FLT3 exon17 unknown unknown FLT3 exon 17, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 17 of the FLT3 gene.
FLT3 exon18 unknown unknown FLT3 exon 18, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 18 of the FLT3 gene.
FLT3 exon19 unknown unknown FLT3 exon 19, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 19 of the FLT3 gene.
FLT3 exon20 unknown unknown FLT3 exon 20, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 20 of the FLT3 gene.
FLT3 exon21 unknown unknown FLT3 exon 21, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 21 of the FLT3 gene.
FLT3 exon22 unknown unknown FLT3 exon 22, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 22 of the FLT3 gene.
FLT3 exon23 unknown unknown FLT3 exon 23, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 23 of the FLT3 gene.
FLT3 fusion fusion unknown FLT3 fusion indicates a fusion of the FLT3 gene, but the fusion partner is unknown.
FLT3 I836X missense unknown FLT3 I836X indicates any Flt3 missense mutation that results in the replacement of the isoleucine (I) at amino acid 836 by a different amino acid.
FLT3 inact mut unknown loss of function FLT3 inact mut indicates that this variant results in a loss of function of the Flt3 protein. However, the specific amino acid change has not been identified.
FLT3 LOH deletion unknown FLT3 LOH indicates the loss of one parental copy of the FLT3 gene, resulting in loss of heterozygosity.
FLT3 mutant unknown unknown FLT3 mutant indicates an unspecified mutation in the FLT3 gene.
FLT3 over exp none no effect FLT3 over exp indicates an over expression of the Flt3 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
FLT3 positive unknown unknown FLT3 positive indicates the presence of FLT3 mRNA and/or protein.
FLT3 rearrange unknown unknown FLT3 rearrangement indicates an unspecified rearrangement of the FLT3 gene.
FLT3 wild-type none no effect Wild-type FLT3 indicates that no mutation has been detected within the FLT3 gene.
HRAS act mut unknown unknown HRAS act mut indicates that the variant results in activation of HRAS downstream signaling. The mechanism causing the activation can include either loss of GTP hydrolysis activity (loss of function) or increased nucleotide exchange rate (gain of function).
HRAS amp none no effect HRAS amplification indicates an increased number of copies of the HRAS gene. However, the mechanism causing the increase is unspecified.
HRAS inact mut unknown loss of function HRAS inact mut indicates that the variant results in failure to activate HRAS downstream signaling. However, the specific amino acid change has not been identified.
HRAS mutant unknown unknown HRAS mutant indicates an unspecified mutation in the HRAS gene.
HRAS over exp none no effect HRAS over exp indicates an over expression of the Hras protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
HRAS positive unknown unknown HRAS positive indicates the presence of HRAS mRNA and/or protein.
HRAS wild-type none no effect Wild-type HRAS indicates that no mutation has been detected within the HRAS gene.
IDH1 act mut unknown gain of function IDH1 act mut indicates that this variant results in a gain of function in the Idh1 protein. However, the specific amino acid change has not been identified.
IDH1 amp none no effect IDH1 amp indicates an increased number of copies of the IDH1 gene. However, the mechanism causing the increase is unspecified.
IDH1 del deletion loss of function IDH1 del indicates a deletion of the IDH1 gene.
IDH1 G97X missense unknown IDH1 G97X indicates any Idh1 missense mutation that results in replacement of the glycine (G) at amino acid 97 by a different amino acid.
IDH1 inact mut unknown loss of function IDH1 inact mut indicates that this variant results in a loss of function of the Idh1 protein. However, the specific amino acid change has not been identified.
IDH1 mutant unknown unknown IDH1 mutant indicates an unspecified mutation in the IDH1 gene.
IDH1 over exp none no effect IDH1 over exp indicates an over expression of the Idh1 protein. However, the mechanism causing the over expression is unspecified.
IDH1 R100X missense unknown IDH1 R100X indicates any Idh1 missense mutation that results in replacement of the arginine (R) at amino acid 100 by a different amino acid.
IDH1 wild-type none no effect Wild-type IDH1 indicates that no mutation has been detected within the IDH1 gene.
IDH1 Y139X missense unknown IDH1 Y139X indicates any Idh1 missense mutation that results in replacement of the tyrosine (Y) at amino acid 139 by a different amino acid.
IDH2 act mut unknown gain of function IDH2 act mut indicates that this variant results in a gain of function in the Idh2 protein. However, the specific amino acid change has not been identified.
IDH2 amp none no effect IDH2 amp indicates an increased number of copies of the Idh2 gene. However, the mechanism causing the increase is unspecified.
IDH2 del deletion loss of function IDH2 del indicates a deletion of the IDH2 gene.
IDH2 inact mut unknown loss of function IDH2 inact mut indicates that this variant results in a loss of function of the Idh2 protein. However, the specific amino acid change has not been identified.
IDH2 mutant unknown unknown IDH2 mutant indicates an unspecified mutation in the IDH2 gene.
IDH2 over exp none no effect IDH2 over exp indicates an over expression of the Idh2 protein. However, the mechanism causing the over expression is unspecified.
IDH2 wild-type none no effect Wild-type IDH2 indicates that no mutation has been detected within the IDH2 gene.
JAK2 act mut unknown gain of function JAK2 act mut indicates that this variant results in a gain of function in the Jak2 protein. However, the specific amino acid change has not been identified.
JAK2 amp none no effect JAK2 amp indicates an increased number of copies of the JAK2 gene. However, the mechanism causing the increase is unspecified.
JAK2 dec exp none no effect JAK2 dec exp indicates decreased expression of the Jak2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
JAK2 del deletion loss of function JAK2 del indicates a deletion of the JAK2 gene.
JAK2 exon12 unknown unknown JAK2 exon 12 indicates an unspecified mutation has occurred in exon 12 (amino acids 505-547) of the JAK2 gene.
JAK2 fusion fusion unknown JAK2 fusion indicates a fusion of the JAK2 gene, but the fusion partner is unknown.
JAK2 inact mut unknown loss of function JAK2 inact mut indicates that this variant results in a loss of function of the Jak2 protein. However, the specific amino acid change has not been identified.
JAK2 LOH deletion unknown JAK2 LOH indicates the loss of one parental copy of the JAK2 gene, resulting in the loss of heterozygosity.
JAK2 loss unknown loss of function JAK2 loss indicates loss of the JAK2 gene, mRNA, and protein.
JAK2 mutant unknown unknown JAK2 mutant indicates an unspecified mutation in the JAK2 gene.
JAK2 over exp none no effect JAK2 over exp indicates an over expression of the Jak2 protein. However, the mechanism causing the over expression is unspecified.
JAK2 rearrange unknown unknown JAK2 rearrange indicates an unspecified rearrangement of the JAK2 gene.
JAK2 wild-type none no effect Wild-type JAK2 indicates that no mutation has been detected within the JAK2 gene.
JAK3 act mut unknown gain of function JAK3 act mut indicates that this variant results in a gain of function in the Jak3 protein. However, the specific amino acid change has not been identified.
JAK3 fusion fusion unknown JAK3 fusion indicates a fusion of the JAK3 gene, but the fusion partner is unknown.
JAK3 inact mut unknown loss of function JAK3 inact mut indicates that this variant results in a loss of function of the Jak3 protein. However, the specific amino acid change has not been identified.
JAK3 mutant unknown unknown JAK3 mutant indicates an unspecified mutation in the JAK3 gene.
JAK3 rearrange unknown unknown JAK3 rearrangement indicates an unspecified rearrangement of the JAK3 gene.
JAK3 wild-type none no effect Wild-type JAK3 indicates that no mutation has been detected within the JAK3 gene.
KIT act mut unknown gain of function KIT act mut indicates that this variant results in a gain of function in the Kit protein. However, the specific amino acid change has not been identified.
KIT amp none no effect KIT amp indicates an increased number of copies of the KIT gene. However, the mechanism causing the increase is unspecified.
KIT D816X missense unknown KIT D816X indicates any Kit missense mutation that results in the replacement of the aspartic acid (D) at amino acid 816 by a different amino acid.
KIT exon11 unknown unknown KIT exon 11 (amino acids 550-592) indicates an unspecified mutation within the juxtamembrane domain has occurred in exon 11 of the KIT gene.
KIT exon13 unknown unknown KIT exon 13 (amino acids 627-664) indicates an unspecified mutation has occurred in exon 13 of the KIT gene.
KIT exon14 unknown unknown KIT exon 14 (amino acids 664-713) indicates an unspecified mutation has occurred in exon 14 of the KIT gene.
KIT exon17 unknown unknown KIT exon 17 (amino acids 788-828) indicates an unspecified mutation has occurred in exon 17 of the KIT gene.
KIT exon18 unknown unknown KIT exon 18 (amino acids 829-866) indicates an unspecified mutation has occurred in exon 18 of the KIT gene.
KIT exon8 unknown unknown KIT exon 8 (amino acids 411-449) indicates an unspecified mutation has occurred in exon 8 of the KIT gene.
KIT exon9 unknown unknown KIT exon 9 (amino acids 449-514) indicates an unspecified mutation has occurred in exon 9 of the KIT gene.
KIT fusion fusion unknown KIT fusion indicates a fusion of the KIT gene, but the fusion partner is unknown.
KIT mutant unknown unknown KIT mutant indicates an unspecified mutation in the KIT gene.
KIT negative unknown loss of function KIT negative indicates a lack of expression of the KIT mRNA and/or protein.
KIT over exp none no effect KIT over exp indicates an over expression of the KIT protein. However, the mechanism causing the over expression is unspecified.
KIT positive unknown unknown KIT positive indicates the presence of KIT mRNA and/or protein.
KIT rearrange unknown unknown KIT rearrangement indicates an unspecified rearrangement of the KIT gene.
KIT T670X missense unknown KIT T670X indicates any KIT missense mutation that results in the replacement of the threonine (T) at amino acid 670 by a different amino acid.
KIT V559X missense unknown KIT V559X indicates any Kit missense mutation that results in the replacement of the valine (V) at amino acid 559 by a different amino acid.
KIT wild-type none no effect Wild-type KIT indicates that no mutation has been detected within the KIT gene.
KMT2A act mut unknown gain of function KMT2A act mut indicates that this variant results in a gain of function in the Kmt2a protein. However, the specific amino acid change has not been identified.
KMT2A amp none no effect KMT2A amplification indicates an increased number of copies of the KMT2A gene. However, the mechanism causing the increase is unspecified.
KMT2A fusion fusion unknown KMT2A fusion indicates a fusion of the KMT2A gene, but the fusion partner is unknown.
KMT2A inact mut unknown loss of function KMT2A inact mut indicates that this variant results in a loss of function of the Kmt2a protein. However, the specific amino acid change has not been identified.
KMT2A mutant unknown unknown KMT2A mutant indicates an unspecified mutation in the KMT2A gene.
KMT2A over exp none no effect KMT2A over exp indicates an over expression of the Kmt2a protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
KMT2A positive unknown unknown KMT2A positive indicates the presence of KMT2A mRNA and/or protein.
KMT2A rearrange unknown unknown KMT2A rearrangement indicates an unspecified rearrangement of the KMT2A gene.
MAP2K1 act mut unknown gain of function MAP2K1 act mut indicates that this variant results in a gain of function in the Map2k1 protein. However, the specific amino acid change has not been identified.
MAP2K1 amp none no effect MAP2K1 amp indicates an increased number of copies of the MAP2K1 gene. However, the mechanism causing the increase is unspecified.
MAP2K1 fusion fusion unknown MAP2K1 fusion indicates a fusion of the MAP2K1 gene, but the fusion partner is unknown.
MAP2K1 inact mut unknown loss of function MAP2K1 inact mut indicates that this variant results in a loss of function of the Map2k1 protein. However, the specific amino acid change has not been identified.
MAP2K1 mutant unknown unknown MAP2K1 mutant indicates an unspecified mutation in the MAP2K1 gene.
MAP2K1 wild-type none no effect Wild-type MAP2K1 indicates that no mutation has been detected within the MAP2K1 gene.
MLH1 del deletion loss of function MLH1 del indicates a deletion of the MLH1 gene.
MLH1 del exon4 deletion unknown MLH1 del exon4 indicates a deletion of exon 4 of the MLH1 gene.
MLH1 del exon5 deletion unknown MLH1 del exon5 indicates a deletion of exon 5 of the MLH1 gene.
MLH1 hypermethylation unknown unknown MLH1 hypermethylation indicates an increased methylation of the MLH1 gene. However, the mechanism causing the hypermethylation is unspecified.
MLH1 inact mut unknown loss of function MLH1 inact mut indicates that this variant results in a loss of function of the Mlh1 protein. However, the specific amino acid change has not been identified.
MLH1 LOH deletion unknown MLH1 LOH indicates the loss of one parental copy of the MLH1 gene, resulting in loss of heterozygosity.
MLH1 loss unknown loss of function MLH1 loss indicates loss of the MLH1 gene, mRNA, and protein.
MLH1 mutant unknown unknown MLH1 mutant indicates an unspecified mutation in the MLH1 gene.
MLH1 negative unknown loss of function MLH1 negative indicates a lack of expression of the MLH1 mRNA and/or protein.
MLH1 positive unknown unknown MLH1 positive indicates the presence of MLH1 mRNA and/or protein.
MSH6 amp none no effect MSH6 amplification indicates an increased number of copies of the MSH6 gene. However, the mechanism causing the increase is unspecified.
MSH6 hypermethylation unknown unknown MSH6 hypermethylation indicates an increased methylation of the MSH6 gene. However, the mechanism causing the hypermethylation is unspecified.
MSH6 inact mut unknown loss of function MSH6 inact mut indicates that this variant results in a loss of function of the Msh6 protein. However, the specific amino acid change has not been identified.
MSH6 loss unknown loss of function MSH6 loss indicates loss of the MSH6 gene, mRNA, and protein.
MSH6 mutant unknown unknown MSH6 mutant indicates an unspecified mutation in the MSH6 gene.
MSH6 negative unknown loss of function MSH6 negative indicates a lack of expression of the MSH6 mRNA and/or protein.
MSH6 positive unknown unknown MSH6 positive indicates the presence of MSH6 mRNA and/or protein.
NRAS A146X missense unknown NRAS A146X indicates any NRAS missense mutation that results in replacement of the alanine (A) at amino acid 146 by a different amino acid.
NRAS A59X missense unknown NRAS A59X indicates any NRAS missense mutation that results in the replacement of the alanine (A) at amino acid 59 by a different amino acid.
NRAS act mut unknown unknown NRAS act mut indicates that the variant results in activation of NRAS downstream signaling. The mechanism causing the activation can include either loss of GTP hydrolysis activity (loss of function) or increased nucleotide exchange rate (gain of function).
NRAS amp none no effect NRAS amplification indicates an increased number of copies of the NRAS gene. However, the mechanism causing the increase is unspecified.
NRAS dec exp none no effect NRAS dec exp indicates decreased expression of the Nras protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
NRAS exon2 unknown unknown NRAS exon 2 indicates an unspecified mutation has occurred in exon 2 of the NRAS gene.
NRAS exon3 unknown unknown NRAS exon 3 indicates an unspecified mutation has occurred in exon 3 of the NRAS gene.
NRAS exon4 unknown unknown NRAS exon 4 indicates an unspecified mutation has occurred in exon 4 of the NRAS gene.
NRAS inact mut unknown loss of function NRAS inact mut indicates that the variant results in failure to activate NRAS downstream signaling. However, the specific amino acid change has not been identified.
NRAS K117X missense unknown NRAS K117X indicates any NRAS missense mutation that results in the replacement of the lysine (K) at amino acid 117 by a different amino acid.
NRAS mutant unknown unknown NRAS mutant indicates an unspecified mutation in the NRAS gene.
NRAS over exp none no effect NRAS over exp indicates an over expression of the Nras protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
NRAS positive unknown unknown NRAS positive indicates the presence of NRAS mRNA and/or protein.
NRAS wild-type none no effect Wild-type NRAS indicates that no mutation has been detected within the NRAS gene.
PBRM1 del deletion loss of function PBRM1 del indicates a deletion of the PBRM1 gene.
PBRM1 inact mut unknown loss of function PBRM1 inact mut indicates that this variant results in a loss of function of the Pbrm1 protein. However, the specific amino acid change has not been identified.
PBRM1 loss unknown loss of function PBRM1 loss indicates loss of the PBRM1 gene, mRNA, and protein.
PBRM1 mutant unknown unknown PBRM1 mutant indicates an unspecified mutation in the PBRM1 gene.
PIK3CA act mut unknown gain of function PIK3CA act mut indicates that this variant results in a gain of function in the Pik3ca protein. However, the specific amino acid change has not been identified.
PIK3CA amp none no effect PIK3CA amplification indicates an increased number of copies of the PIK3CA gene. However, the mechanism causing the increase is unspecified.
PIK3CA dec exp none no effect PIK3CA dec exp indicates decreased expression of the Pik3ca protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
PIK3CA E542X missense unknown PIK3CA E542X indicates any Pik3ca missense mutation that results in the replacement of the glutamic acid (E) at amino acid 542 by a different amino acid.
PIK3CA exon10 unknown unknown PIK3CA exon 10 indicates an unspecified mutation has occurred in exon 10 (corresponding to amino acids 514 to 555) of the PIK3CA gene. PIK3CA exon 10 is sometimes reported as exon 9, when only coding exons are considered in numbering.
PIK3CA exon20 unknown unknown PIK3CA exon 20 indicates an unspecified mutation has occurred in exon 20 (corresponding to amino acids 929 to 979) of the PIK3CA gene. PIK3CA exon 21 (corresponding to amino acids 979 to 1068) is sometimes reported as exon 20, when only coding exons are considered in numbering.
PIK3CA exon21 unknown unknown PIK3CA exon 21 indicates an unspecified mutation has occurred in exon 21 (corresponding to amino acids 979 to 1068) of the PIK3CA gene. PIK3CA exon 21 is sometimes reported as exon 20, when only coding exons are considered in numbering.
PIK3CA exon5 unknown unknown PIK3CA exon 5 indicates an unspecified mutation has occurred in exon 5 (corresponding to amino acids 272 to 353) of the PIK3CA gene. PIK3CA exon 5 is sometimes reported as exon 4, when only coding exons are considered in numbering.
PIK3CA exon8 unknown unknown PIK3CA exon 8 indicates an unspecified mutation has occurred in exon 8 (corresponding to amino acids 418 to 468) of the PIK3CA gene. PIK3CA exon 8 is sometimes reported as exon 7, when only coding exons are considered in numbering.
PIK3CA exon9 unknown unknown PIK3CA exon 9 indicates an unspecified mutation has occurred in exon 9 (corresponding to amino acids 469 to 513) of the PIK3CA gene. PIK3CA exon 10 (corresponding to amino acids 514 to 555) is sometimes reported as exon 9, when only coding exons are considered in numbering.
PIK3CA inact mut unknown loss of function PIK3CA inact mut indicates that this variant results in a loss of function of the Pik3ca protein. However, the specific amino acid change has not been identified.
PIK3CA mutant unknown unknown PIK3CA mutant indicates an unspecified mutation within the PIK3CA gene.
PIK3CA over exp none no effect PIK3CA over exp indicates an over expression of the Pik3ca protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
PIK3CA positive unknown unknown PIK3CA positive indicates the presence of PIK3CA mRNA and/or protein.
PIK3CA Q546X missense unknown PIK3CA Q546X indicates any PIK3CA missense mutation that results in replacement of the glutamine (Q) at amino acid 546 by a different amino acid.
PIK3CA wild-type none no effect Wild-type PIK3CA indicates that no mutation has been detected within the PIK3CA gene.
PTEN dec exp none no effect PTEN dec exp indicates decreased expression of the Pten protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
PTEN del deletion loss of function PTEN del indicates a deletion of the PTEN gene.
PTEN del exon1-2 deletion unknown PTEN del exon1-2 indicates the deletion of exons 1-2 of the PTEN gene.
PTEN fusion fusion unknown PTEN fusion indicates a fusion of the PTEN gene, but the fusion partner is unknown.
PTEN inact mut unknown loss of function PTEN inact mut indicates that this variant results in a loss of function of the Pten protein. However, the specific amino acid change has not been identified.
PTEN LOH deletion unknown PTEN LOH indicates the loss of one parental copy of the PTEN gene, resulting in loss of heterozygosity.
PTEN loss unknown loss of function PTEN loss indicates a loss of the PTEN gene, mRNA, and protein, which leads to suppression of Ar-dependent gene expression (PMID: 21620777), epithelial-mesenchymal transition in cell culture (PMID: 20032390), and promotes KRAS-dependent tumor formation (PMID: 20807812), and decreased apoptosis and increased cell survival in a mouse model (PMID: 12782594). PTEN loss has been identified in a number of cancers (PMID: 30738865), including prostate cancer (PMID: 29460925) and glioblastoma (PMID: 9331071).
PTEN mutant unknown unknown PTEN mutant indicates an unspecified mutation in the PTEN gene.
PTEN negative unknown loss of function PTEN negative indicates a lack of the PTEN gene, mRNA, and/or protein.
PTEN over exp none no effect PTEN over exp indicates an over expression of the Pten protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
PTEN positive unknown unknown PTEN positive indicates the presence of PTEN mRNA and/or protein.
PTEN rearrange unknown unknown PTEN rearrangement indicates an unspecified rearrangement of the PTEN gene.
PTEN wild-type none no effect Wild-type PTEN indicates that no mutation has been detected within the PTEN gene.
RAD51B amp none no effect RAD51B amplification indicates an increased number of copies of the RAD51B gene. However, the mechanism causing the increase is unspecified.
RAD51B del deletion loss of function RAD51B del indicates a deletion of the RAD51B gene.
RAD51B fusion fusion unknown RAD51B fusion indicates a fusion of the RAD51B gene, but the fusion partner is unknown.
RAD51B inact mut unknown loss of function RAD51B inact mut indicates that this variant results in a loss of function of the Rad51b protein. However, the specific amino acid change has not been identified.
RAD51B loss unknown loss of function RAD51B loss indicates loss of the RAD51B gene, mRNA, and protein.
RAD51B mutant unknown unknown RAD51B mutant indicates an unspecified mutation in the RAD51B gene.
RAD51B over exp none no effect RAD51B over exp indicates an over expression of the Rad51b protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
RAD51B rearrange unknown unknown RAD51B rearrange indicates an unspecified rearrangement of the RAD51B gene.
RAD51B wild-type none no effect Wild-type RAD51B indicates that no mutation has been detected within the RAD51B gene.
RAD51C amp none no effect RAD51C amplification indicates an increased number of copies of the RAD51C gene. However, the mechanism causing the increase is unspecified.
RAD51C del deletion loss of function RAD51C del indicates a deletion of the RAD51C gene.
RAD51C inact mut unknown loss of function RAD51C inact mut indicates that this variant results in a loss of function of the Rad51c protein. However, the specific amino acid change has not been identified.
RAD51C loss unknown loss of function RAD51C loss indicates loss of the RAD51C gene, mRNA, and protein.
RAD51C mutant unknown unknown RAD51C mutant indicates an unspecified mutation in the RAD51C gene.
RAD51C over exp none no effect RAD51C over exp indicates an over expression of the Rad51c protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
RAD51D amp none no effect RAD51D amplification indicates an increased number of copies of the RAD51D gene. However, the mechanism causing the increase is unspecified.
RAD51D del deletion loss of function RAD51D del indicates a deletion of the RAD51D gene.
RAD51D inact mut unknown loss of function RAD51D inact mut indicates that this variant results in a loss of function of the Rad51d protein. However, the specific amino acid change has not been identified.
RAD51D loss unknown loss of function RAD51D loss indicates loss of the RAD51D gene, mRNA, and protein.
RAD51D mutant unknown unknown RAD51D mutant indicates an unspecified mutation in the RAD51D gene.
RAD54L amp none no effect RAD54L amplification indicates an increased number of copies of the RAD54L gene. However, the mechanism causing the increase is unspecified.
RAD54L del deletion loss of function RAD54L del indicates a deletion of the RAD54L gene.
RAD54L inact mut unknown loss of function RAD54L inact mut indicates that this variant results in a loss of function of the Rad54l protein. However, the specific amino acid change has not been identified.
RAD54L loss unknown loss of function RAD54L loss indicates loss of the RAD54L gene, mRNA, and protein.
RAD54L mutant unknown unknown RAD54L mutant indicates an unspecified mutation in the RAD54L gene.
RAD54L over exp none no effect RAD54L over exp indicates an over expression of the Rad54l protein and/or mRNA. However, the mechanism causing the over expression is unspecified.
RB1 dec exp none no effect RB1 dec exp indicates decreased expression of the Rb1 protein and/or mRNA. However, the mechanism causing the decrease is unspecified.
RB1 del deletion loss of function RB1 del indicates a deletion of the RB1 gene.
RB1 inact mut unknown loss of function RB1 inact mut indicates that this variant results in a loss of function of the Rb1 protein. However, the specific amino acid change has not been identified.
RB1 loss unknown loss of function RB1 loss indicates loss of the RB1 gene, mRNA, and protein.
RB1 mutant unknown unknown RB1 mutant indicates an unspecified mutation in the RB1 gene.
RB1 negative unknown loss of function RB1 negative indicates a lack of the RB1 gene, mRNA, and/or protein.
RB1 positive unknown unknown RB1 positive indicates the presence of RB1 mRNA and/or protein.
RB1 wild-type none no effect Wild-type RB1 indicates that no mutations have been detected within the RB1 gene.
RET A883X missense unknown RET A883X indicates any Ret missense mutation that results in replacement of the alanine (A) at amino acid 883 by a different amino acid.
RET act mut unknown gain of function RET act mut indicates that this variant results in a gain of function in the Ret protein. However the specific amino acid change has not been identified.
RET amp none no effect RET amp indicates an increased number of copies of the RET gene. However, the mechanism causing the increase is unspecified.
RET C609X missense unknown RET C609X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 609 by a different amino acid.
RET C611X missense unknown RET C611X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 611 by a different amino acid.
RET C618X missense unknown RET C618X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 618 by a different amino acid.
RET C620X missense unknown RET C620X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 620 by a different amino acid.
RET C630X missense unknown RET C630X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 630 by a different amino acid.
RET C634X missense unknown RET C634X indicates any Ret missense mutation that results in replacement of the cysteine (C) at amino acid 634 by a different amino acid.
RET E768X missense unknown RET E768X indicates any Ret missense mutation that results in replacement of the glutamic acid (E) at amino acid 768 by a different amino acid.
RET fusion fusion unknown RET fusion indicates a fusion of the RET gene, but the fusion partner is unknown.
RET inact mut unknown loss of function RET inact mut indicates that this variant results in a loss of function of the Ret protein. However, the specific amino acid change has not been identified.
RET L790X missense unknown RET L790X indicates any Ret missense mutation that results in replacement of the leucine (L) at amino acid 790 by a different amino acid.
RET M918X missense unknown RET M918X indicates any Ret missense mutation that results in replacement of the methionine (M) at amino acid 918 by a different amino acid.
RET mutant unknown unknown RET mutant indicates an unspecified mutation in the RET gene.
RET over exp none no effect RET over exp indicates an over expression of the Ret protein. However, the mechanism causing the over expression is unspecified.
RET positive unknown unknown RET positive indicates the presence of RET mRNA and/or protein.
RET rearrange unknown unknown RET rearrangement indicates an unspecified rearrangement of the RET gene.
RET S891X missense unknown RET S891X indicates any Ret missense mutation that results in replacement of the serine (S) at amino acid 891 by a different amino acid.
RET V804X missense unknown RET V804X indicates any Ret missense mutation that results in replacement of the valine (V) at amino acid 804 by a different amino acid.
RET wild-type none no effect Wild-type RET indicates that no mutation has been detected within the RET gene.
RET Y791X missense unknown RET Y791X indicates any Ret missense mutation that results in replacement of the tyrosine (Y) at amino acid 791 by a different amino acid.
ROS1 act mut unknown gain of function ROS1 act mut indicates that this variant results in a gain of function in the Ros1 protein. However, the specific amino acid change has not been identified.
ROS1 amp none no effect ROS1 amplification indicates an increased number of copies of the ROS1 gene. However, the mechanism causing the increase is unspecified.
ROS1 dec exp none no effect ROS1 dec exp indicates decreased expression of the Ros1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.
ROS1 del deletion loss of function ROS1 del indicates a deletion of the ROS1 gene.
ROS1 fusion fusion unknown ROS1 fusion indicates a fusion of the ROS1 gene, but the fusion partner is unknown.
ROS1 inact mut unknown loss of function ROS1 inact mut indicates that this variant results in a loss of function of the Ros1 protein. However, the specific amino acid change has not been identified.
ROS1 mutant unknown unknown ROS1 mutant indicates an unspecified mutation in the ROS1 gene.
ROS1 negative unknown loss of function ROS1 negative indicates a lack of the ROS1 gene, mRNA, and/or protein.
ROS1 positive unknown unknown ROS1 positive indicates the presence of ROS1 mRNA and/or protein. ROS1 positive has been used alternatively to refer to presence of a ROS1 fusion or rearrangement. For related data, refer to ROS1 fusion or ROS1 rearrange in CKB.
ROS1 rearrange unknown unknown ROS1 rearrange indicates an unspecified rearrangement of the ROS1 gene.
ROS1 wild-type none no effect Wild-type ROS1 indicates that no mutation has been detected within the ROS1 gene.
SMARCA4 amp none no effect SMARCA4 amplification indicates an increased number of copies of the SMARCA4 gene. However, the mechanism causing the increase is unspecified.
SMARCA4 del deletion loss of function SMARCA4 del indicates a deletion of the SMARCA4 gene.
SMARCA4 inact mut unknown loss of function SMARCA4 inact mut indicates that this variant results in a loss of function of the Smarca4 protein. However, the specific amino acid change has not been identified.
SMARCA4 loss unknown loss of function SMARCA4 loss indicates loss of the SMARCA4 gene, mRNA, and protein.
SMARCA4 mutant unknown unknown SMARCA4 mutant indicates an unspecified mutation in the SMARCA4 gene.
SMARCA4 negative unknown loss of function SMARCA4 negative indicates a lack of the SMARCA4 gene, mRNA, and/or protein.
SMARCA4 positive unknown unknown SMARCA4 positive indicates the presence of SMARCA4 mRNA and/or protein.
SMARCB1 amp none no effect SMARCB1 amplification indicates an increased number of copies of the SMARCB1 gene. However, the mechanism causing the increase is unspecified.
SMARCB1 inact mut unknown loss of function SMARCB1 inact mut indicates that this variant results in a loss of function of the Smarcb1 protein. However, the specific amino acid change has not been identified.
SMARCB1 loss unknown loss of function SMARCB1 loss indicates loss of the SMARCB1 gene, mRNA, and protein.
SMARCB1 mutant unknown unknown SMARCB1 mutant indicates an unspecified mutation in the SMARCB1 gene.
SMARCB1 negative unknown loss of function SMARCB1 negative indicates a lack of the SMARCB1 gene, mRNA, and/or protein.
SMARCB1 positive unknown unknown SMARCB1 positive indicates the presence of SMARCB1 mRNA and/or protein.
SMARCB1 wild-type none no effect Wild-type SMARCB1 indicates that no mutation has been detected within the SMARCB1 gene.
SMARCE1 mutant unknown unknown SMARCE1 mutant indicates an unspecified mutation in the SMARCE1 gene.
TET2 del deletion loss of function TET2 del indicates a deletion of the TET2 gene.
TET2 inact mut unknown loss of function TET2 inact mut indicates that this variant results in a loss of Tet2 protein function. However, the specific amino acid change has not been identified.
TET2 loss unknown loss of function TET2 loss indicates loss of the TET2 gene, mRNA, and protein.
TET2 mutant unknown unknown TET2 mutant indicates an unspecified mutation in the TET2 gene.
TET2 wild-type none no effect Wild-type TET2 indicates that no mutations have been detected within the TET2 gene.
TP53 act mut unknown gain of function TP53 act mut indicates that this variant results in a gain of function in the Tp53 protein. However, the specific amino acid change has not been identified.
TP53 amp none no effect TP53 amp indicates an increased number of copies of the TP53 gene. However, the mechanism causing the increase is unspecified.
TP53 dec exp none no effect TP53 dec exp indicates decreased expression of the Tp53 protein. However, the mechanism causing the decreased expression is unspecified.
TP53 del deletion loss of function TP53 del indicates a deletion of the TP53 gene.
TP53 exon10 unknown unknown TP53 exon 10 indicates an unspecified mutation has occurred in exon 10 of the TP53 gene.
TP53 exon11 unknown unknown TP53 exon 11 indicates an unspecified mutation has occurred in exon 11 of the TP53 gene.
TP53 exon2 unknown unknown TP53 exon 2 indicates an unspecified mutation has occurred in exon 2 of the TP53 gene.
TP53 exon4 unknown unknown TP53 exon 4 indicates an unspecified mutation has occurred in exon 4 of the TP53 gene.
TP53 exon5 unknown unknown TP53 exon 5 indicates an unspecified mutation has occurred in exon 5 of the TP53 gene.
TP53 exon6 unknown unknown TP53 exon 6 indicates an unspecified mutation has occurred in exon 6 of the TP53 gene.
TP53 exon7 unknown unknown TP53 exon 7 indicates an unspecified mutation has occurred in exon 7 of the TP53 gene.
TP53 exon8 unknown unknown TP53 exon 8 indicates an unspecified mutation has occurred in exon 8 of the TP53 gene.
TP53 exon9 unknown unknown TP53 exon 9 indicates an unspecified mutation has occurred in exon 9 of the TP53 gene.
TP53 inact mut unknown loss of function TP53 inact mut indicates that this variant results in a loss of function of the Tp53 protein. However, the specific amino acid change has not been identified.
TP53 loss unknown loss of function TP53 loss indicates loss of the TP53 gene, mRNA, and protein.
TP53 mutant unknown unknown TP53 mutant indicates an unspecified mutation within the TP53 gene.
TP53 negative unknown loss of function TP53 negative indicates a lack of the TP53 gene, mRNA, and/or protein.
TP53 over exp none no effect TP53 over exp indicates an over expression of the Tp53 protein. However, the mechanism causing the over expression is unspecified.
TP53 positive unknown unknown TP53 positive indicates the presence of TP53 mRNA and/or protein.
TP53 R175X missense unknown TP53 R175X indicates a hotspot mutation resulting in an amino acid change at codon 175 of the Tp53 protein, which often results in a loss of Tp53 protein function.
TP53 R273X missense unknown TP53 R273X indicates a hotspot mutation resulting in an amino acid change at codon 273 of the Tp53 protein, which often results in a loss of Tp53 protein function.
TP53 wild-type none no effect Wild-type TP53 indicates that no mutation has been detected within the TP53 gene.
TSC1 del deletion loss of function TSC1 del indicates a deletion of the TSC1 gene.
TSC1 inact mut unknown loss of function TSC1 inact mut indicates that this variant results in a loss of function of the Tsc1 protein. However, the specific amino acid change has not been identified.
TSC1 LOH deletion unknown TSC1 LOH indicates the loss of one parental copy of the TSC1 gene, resulting in loss of heterozygosity.
TSC1 loss unknown loss of function TSC1 loss indicates loss of the TSC1 gene, mRNA, and protein.
TSC1 mutant unknown unknown TSC1 mutant indicates an unspecified mutation in the TSC1 gene.
TSC1 wild-type none no effect Wild-type TSC1 indicates that no mutation has been detected within the TSC1 gene.
TSC2 amp none no effect TSC2 amplification indicates an increased number of copies of the TSC2 gene. However, the mechanism causing the increase is unspecified.
TSC2 del deletion loss of function TSC2 del indicates a deletion of the TSC2 gene.
TSC2 inact mut unknown loss of function TSC2 inact mut indicates that this variant results in a loss of function of the Tsc2 protein. However, the specific amino acid change has not been identified.
TSC2 loss unknown loss of function TSC2 loss indicates loss of the TSC2 gene, mRNA, and protein.
TSC2 mutant unknown unknown TSC2 mutant indicates an unspecified mutation in the TSC2 gene.
TSC2 wild-type none no effect Wild-type TSC2 indicates that no mutation has been detected within the TSC2 gene.
VHL amp none no effect VHL amplification indicates an increased number of copies of the VHL gene. However, the mechanism causing the increase is unspecified.
VHL del deletion loss of function VHL del indicates a deletion of the VHL gene.
VHL inact mut unknown loss of function VHL inact mut indicates that this variant results in a loss of function of the Vhl protein. However, the specific amino acid change has not been identified.
VHL loss unknown loss of function VHL loss indicates loss of the VHL gene, mRNA, and protein.
VHL mutant unknown unknown VHL mutant indicates an unspecified mutation in the VHL gene.
VHL negative unknown loss of function VHL negative indicates a lack of the VHL gene, mRNA, and/or protein.
VHL over exp none no effect VHL over exp indicates an over expression of the Vhl protein. However, the mechanism causing the over expression is unspecified.
VHL wild-type none no effect Wild-type VHL indicates that no mutation has been detected within the VHL gene.
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References